Astrana Health (ASTH) 10-Q 15 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 09, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Entity Registrant Name	Apollo Medical Holdings, Inc.
Entity Central Index Key	1,083,446
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	AMEH
Entity Common Stock, Shares Outstanding		33,334,059

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 103,731,761	$ 99,749,199
Restricted cash - short-term	18,028,116	18,005,661
Fiduciary cash	1,386,474	2,017,437
Investment in marketable securities	1,138,477	1,143,095
Receivables, net	52,805,123	20,117,304
Prepaid expenses and other current assets	3,525,437	3,126,866
Total current assets	180,615,388	144,159,562
Noncurrent assets
Land, property and equipment, net	13,700,034	13,814,306
Intangible assets, net	99,138,657	103,533,558
Goodwill	188,933,191	189,847,202
Loans receivable - related parties	5,000,000	5,000,000
Loan receivable	10,000,000	10,000,000
Investments in other entities - equity method	21,875,500	21,903,524
Restricted cash - long-term	745,293	745,235
Other assets	1,585,850	1,632,406
Total noncurrent assets	340,978,525	346,476,231
Total assets	521,593,913	490,635,793
Current liabilities
Lines of credit	5,000,000	5,025,000
Accounts payable and accrued expenses	12,110,530	13,279,620
Incentives payable	14,900,000	21,500,000
Fiduciary accounts payable	1,386,474	2,017,437
Medical liabilities	69,110,826	63,972,318
Income taxes payable	7,614,669	3,198,495
Bank loan, short-term	394,783	510,391
Capital lease obligations	99,480	98,738
Total current liabilities	110,616,762	109,601,999
Noncurrent liabilities
Deferred tax liability	30,055,819	24,916,598
Liability for unissued equity shares	1,185,025	1,185,025
Dividends payable	18,000,000	18,000,000
Capital lease obligations, net of current portion	593,852	619,001
Total noncurrent liabilities	49,834,696	44,720,624
Total liabilities	160,451,458	154,322,623
Commitments and Contingencies (Note 11)
Mezzanine equity
Noncontrolling interest in Allied Pacific of California IPA (“APC”)	190,654,312	172,129,744
Stockholders’ equity
Common stock, par value $0.001; 100,000,000 shares authorized, 32,652,295 and 32,304,876 shares outstanding, excluding 1,682,110 shares held by APC, at March 31, 2018 and December 31, 2017, respectively (see Note 10)	32,653	32,305
Additional paid-in capital	160,736,190	158,181,192
Retained earnings	4,897,454	1,734,531
Stockholders' Equity Attributable to Parent	165,666,297	159,948,028
Noncontrolling interest	4,821,846	4,235,398
Total stockholders’ equity	170,488,143	164,183,426
Total liabilities, mezzanine equity and stockholders’ equity	521,593,913	490,635,793
Series A Preferred Stock [Member]
Stockholders’ equity
Preferred Stock Value	0	0
Series B Preferred Stock [Member]
Stockholders’ equity
Preferred Stock Value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares outstanding	32,652,295	32,304,876
Treasury Stock, Common, Shares	1,682,110	1,682,110
Series A Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,111,111	1,111,111
Preferred Stock, Shares Outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	555,555	555,555
Preferred Stock, Shares Outstanding	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue
Capitation, net	$ 85,905,284	$ 64,716,133
Risk pool settlements and incentives	17,986,736	11,137,200
Management fee income	12,074,572	6,537,110
Fee-for-service, net	7,748,109	2,663,913
Other income	452,026	281,706
Total revenue	124,166,727	85,336,062
Expenses
Cost of services	84,670,608	59,607,514
General and administrative expenses	11,735,898	5,211,633
Depreciation and amortization	5,058,512	4,836,351
Total expenses	101,465,018	69,655,498
Income from operations	22,701,709	15,680,564
Other income (expense)
(Loss) income from equity method investments	(28,024)	2,227,262
Interest expense	(85,001)	(811)
Interest income	269,818	182,285
Change in fair value of derivative instrument	0	1,522,222
Other income	87,993	1,514
Total other income, net	244,786	3,932,472
Income before provision for income taxes	22,946,495	19,613,036
Provision for income taxes	7,228,840	7,889,245
Net income	15,717,655	11,723,791
Net income attributable to noncontrolling interests	13,557,200	7,374,130
Net income attributable to Apollo Medical Holdings, Inc.	$ 2,160,455	$ 4,349,661
Earnings per share - basic	$ 0.07	$ 0.17
Earnings per share - diluted	$ 0.06	$ 0.15
Weighted average shares of common stock outstanding - basic	32,421,467	25,067,954
Weighted average shares of common stock outstanding - diluted	38,098,373	28,445,647

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities
Net income	$ 15,717,655	$ 11,723,791
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	5,058,512	4,836,351
Loss on disposal of property and equipment	41,782	0
Share-based compensation	833,944	321,233
Unrealized loss from investment in equity securities	8,550	0
Change in fair value of derivative instrument	0	(1,522,222)
Loss (income) from equity method investments	28,024	(2,227,262)
Deferred tax	2,807,407	2,109,535
Changes in operating assets and liabilities:
Receivable, net	(21,087,819)	14,410,196
Prepaid expenses and other current assets	(398,571)	(428,871)
Other assets	(59,444)	(54,368)
Accounts payable and accrued expenses	(1,169,363)	(2,350,949)
Incentives payable	(6,600,000)	(9,721,645)
Medical liabilities	5,138,508	(257,945)
Income taxes payable	4,416,174	4,267,804
Net cash provided by operating activities	4,735,359	21,105,648
Cash flows from investing activities
Purchases of marketable securities	(3,932)	(1,301)
Advances to related parties - loans receivable	0	(5,000,000)
Dividends received from equity method investments	0	1,000,000
Proceeds on sale of investments - cost method	0	25,000
Purchases of property and equipment	(485,121)	(318,821)
Net cash used in investing activities	(489,053)	(4,295,122)
Cash flows from financing activities
Repayment of bank loan	(140,608)	0
Dividends paid	(2,000,000)	(8,750,000)
Change in noncontrolling interest capital	0	(27,500)
Payment of capital lease obligations	(24,407)	(30,980)
Proceeds from exercise of stock options and warrants	1,923,784	425,025
Net cash used in financing activities	(241,231)	(8,383,455)
Net increase in cash, cash equivalents and restricted cash	4,005,075	8,427,071
Cash, cash equivalents and restricted cash, beginning of period	118,500,095	54,925,712
Cash, cash equivalents and restricted cash, end of period	122,505,170	63,352,783
Supplemental disclosures of cash flow information
Cash paid for income taxes	0	1,511,000
Cash paid for interest	73,610	811
Supplemental disclosures of non-cash investing and financing activities
Cashless exercise of stock options	43	0
Reclassification of stock options exercised to liability for unissued common shares	0	425,025
Deferred tax liability adjustment to goodwill	914,011	0
Cumulative effect adjustment for ASC 606 included in accounts receivable	11,600,000	0
Cumulative effect adjustment for ASC 606 included in deferred tax liabilities	3,246,098	0
Reclassification of fiduciary cash to payable	630,963	32,485
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	103,731,761	63,251,651
Restricted cash - long-term - letters of credit	745,293	101,132
Restricted cash - short-term - distributions to former NMM shareholders	18,028,116	0
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 122,505,170	$ 63,352,783

Description of Business

Description of Business	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Description of Business Overview Apollo Medical Holdings, Inc. (“ApolloMed”), entered into an Agreement and Plan of Merger dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017) (the “Merger Agreement”) among ApolloMed, Apollo Acquisition Corp., a California corporation and wholly-owned subsidiary of ApolloMed, Network Medical Management, Inc. (“NMM”), and Kenneth Sim, M.D., not individually but in his capacity as the representative of the shareholders of NMM (the “Merger”). The Merger closed and became effective on December 8, 2017 (the “Closing”) (see Note 3). As a result of the Merger, NMM is now a wholly-owned subsidiary of ApolloMed and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed. For accounting purposes, the Merger is treated as a “reverse acquisition” and NMM is considered the accounting acquirer and ApolloMed the accounting acquiree. Accordingly, as of the Closing, NMM’s historical results of operations replaced ApolloMed’s historical results of operations for all periods prior to the Merger, and the results of operations of both companies are included in the accompanying consolidated financial statements for all periods following the Merger. Effective as of the Closing, ApolloMed’s board of directors approved a change in ApolloMed’s fiscal year end from March 31 to December 31, to correspond with NMM’s fiscal year end prior to the Merger. The combined company, following the Merger, together with its affiliated physician groups and consolidated entities (collectively, the “Company”) is a physician-centric integrated population health management company working to provide coordinated, outcomes-based medical care in a cost-effective manner and serves patients in California, the majority of whom are covered by private or public insurance such as Medicare, Medicaid and health maintenance organizations (“HMOs”), with a small portion of the Company’s revenue coming from non-insured patients. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company’s physician network consists of primary care physicians, specialist physicians and hospitalists. The Company operates primarily through the following subsidiaries of ApolloMed: NMM, Apollo Medical Management, Inc. (“AMM”), APA ACO, Inc. (“APAACO”) and Apollo Care Connect, Inc. (“Apollo Care Connect”), and their consolidated entities. NMM was formed in 1994 as a management service organization (“MSO”) for the purposes of providing management services to medical companies and independent practice associations (“IPAs”). The management services cover primarily billing, collection, accounting, administrative, quality assurance, marketing, compliance and education. Allied Physicians of California IPA, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (“APC”) was incorporated on August 17, 1992 for the purpose of arranging health care services as an IPA. APC has contracts with various health maintenance organizations (“HMOs”) or licensed health care service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of health care services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering health care services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs. On July 1, 1999, APC entered into an amended and restated management and administrative services agreement with NMM (initial management services agreement was entered into in 1997) for an initial fixed term of 30 4.90 4.95 Concourse Diagnostic Surgery Center, LLC (“CDSC”) was formed on March 25, 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, is organized by a group of highly qualified physicians, and the surgical center utilizes some of the most advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare Certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. During 2011, APC invested $ 625,000 41.59 43.80 43.43 APC also holds a 40 APC-LSMA was formed on October 15, 2012 as a designated shareholder professional corporation and Dr. Thomas Lam, a shareholder, Chief Executive and Financial Officer of APC and Co-CEO of ApolloMed is a nominee shareholder of APC. APC makes all the investment decisions on behalf of APC-LSMA, funds these investments and receives all the distributions from the investments. APC has the obligation to absorb losses or rights to receive benefits from all the investments made by APC-LSMA. APC-LSMA’s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC who is the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, which includes: The IPA line of business of LaSalle Medical Associates (“LMA”), Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”), Diagnostic Medical Group (“DMG”) and AHMC International Cancer Center (“ICC”). ICC was formed on September 2, 2010 in the state of California. ICC is a Professional Medical California Corporation and has entered into agreements with organizations such as HMOs, IPAs, medical groups and other purchasers of medical services for the arrangement of services to subscribers or enrollees. On November 15, 2016, APC-LSMA, a holding company of APC, agreed to purchase and acquire from ICC 40 400,000 Universal Care Acquisition Partners, LLC (“UCAP”), a 100 APAACO, jointly owned by NMM and AMM, participates in the next generation accountable care organization model (“NGACO Model”) of the Centers for Medicare & Medicaid Services (“CMS”) as of January 2017. The NGACO Model is a new CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. In addition to APAACO, NMM and AMM operated three accountable care organizations (“ACOs”) that participated in the Medicare Shared Savings Program (“MSSP”), the goal of which is to improve the quality of patient care and outcomes through more efficient and coordinated approach among providers. MSSP revenues are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and are contingent on various factors, including achievement of the minimum savings rate for the relevant period. Such payments are earned and made on an “all or nothing” basis. In 2012, ApolloMed formed an ACO, ApolloMed Accountable Care Organization, Inc. (“ApolloMed ACO”) to participate in the MSSP. On November 11, 2015, NMM, ACO Acquisition Corporation, and APCN-ACO, A Medical Professional Corp. (“APCN-ACO”) entered into a reorganization agreement whereby ACO Acquisition Corporation, a newly organized entity in which NMM is its sole shareholder, merged with APCN-ACO, effective on January 8, 2016, resulting in APCN-ACO becoming a wholly owned subsidiary of NMM. On December 18, 2016, NMM, ACO Acquisition Corporation #2, and Allied Physicians ACO, LLC (“AP-ACO”) entered into a reorganization agreement whereby ACO Acquisition Corporation #2, a newly organized entity in which NMM is its sole shareholder, merged into AP-ACO, effective on December 20, 2016, resulting in AP-ACO becoming a wholly owned subsidiary of NMM. As the Company is transitioning to the NGACO Model, patients and physicians with the three ACOs have substantially been transferred to APAACO. Effective on December 31, 2017, APCN-ACO’s MSSP participation agreement with CMS was terminated. Effective on December 31, 2016, AP-ACO’s MSSP participation agreement with CMS was terminated. Effective on December 31, 2017, ApolloMed ACO’s MSSP participation agreement with CMS was terminated. In conjunction with the Merger, ApolloMed sold to APC-LSMA all the issued and outstanding shares of capital stock of Maverick Medical Group, Inc. (“MMG”). MMG has historically been included in the consolidated financial statements filed by ApolloMed. AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, which consist of ApolloMed Hospitalists (“AMH”), a hospitalist company, Southern California Heart Centers (“SCHC”), Bay Area Hospitalist Associates (“BAHA”), a medical corporation, ApolloMed Care Clinic (“ACC”) and AKM Medical Group, Inc. (“AKM”). AMH provides hospitalist, intensivist and physician advisor services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. BAHA operates a hospitalist, intensivist and post-acute care practice with a presence at three acute care hospitals, one long-term acute care hospital and several skilled nursing facilities. ACC and AKM are no longer active to any material extent. Apollo Care Connect, a wholly-owned subsidiary of ApolloMed, provides a cloud and mobile-based population health management platform that includes digital care plans, a case management module, connectivity with multiple healthcare tracking devices and the ability to integrate with multiple electronic health records to capture clinical data. ApolloMed also has a controlling interest in Apollo Palliative Services, LLC (“APS”), which owns two Los Angeles-based companies, Best Choice Hospice Care, LLC (“BCHC”) and Holistic Care Home Health Agency, Inc. (“HCHHA”) and provides palliative care services. ApolloMed also operated Pulmonary Critical Care Management, Inc. (“PCCM”) and Verdugo Medical Management, Inc. (“VMM”), which operated as physician practice management companies. PCCM and VMM are no longer active to any material extent.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Basis of Presentation and Summary of Significant Accounting Policies The accompanying condensed consolidated balance sheet at December 31, 2017, has been derived from audited consolidated financial statements but do not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S. GAAP”). The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the U.S. Securities and Exchange Commission (“SEC”) on April 2, 2018. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made in the condensed consolidated financial statements. The condensed consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary to make the condensed consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. The Company’s quarterly results fluctuate. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any future periods. The condensed consolidated balance sheets as of December 31, 2017 and March 31, 2018, includes the accounts of ApolloMed, its consolidated subsidiaries NMM, including NMM’s subsidiaries, APCN-ACO and AP-ACO, AMM, APAACO and Apollo Care Connect, NMM’s consolidated VIE, APC, APC’s subsidiary, UCAP, and APC’s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2017, includes NMM, its consolidated VIE, APC, APC’s subsidiary, UCAP, and APC’s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2018, includes ApolloMed, its consolidated subsidiaries NMM, AMM, APAACO and Apollo Care Connect, NMM’s consolidated VIE, APC, APC’s subsidiary, UCAP, and APC’s consolidated VIEs, CDSC, APC-LSMA and ICC. All material intercompany balances and transactions have been eliminated in consolidation. The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination. The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its condensed consolidated financial statements in the aggregate, including all activities in one reportable segment. The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including incurred, but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivable (including constraints, completion factors and the modified retrospective adjustments), income taxes and valuation of share-based compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions. Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the Company’s reported revenue, net income, cash flows or total assets. The Company’s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents. The Company maintains its cash in deposit accounts with several banks, which at times may exceed the Federal Deposit Insurance Corporation (“FDIC”)’s insured limits. The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of March 31, 2018, the Company’s deposit accounts with banks exceeded the FDIC’s insured limit by approximately $ 135.0 At times, APC is required to maintain a reserve fund by certain health plans, which are held in certificate of deposit accounts with initial maturities of six months from the date of purchase and interest rates ranging from 0.05 0.10 18,028,116 18,005,661 18,000,000 The Company’s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool, incentive receivables and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected. Capitation and claims receivable relate to the health plan’s capitation, which is received by the Company in the following month of service. Risk pool and incentive receivables mainly consist of the Company’s full risk pool receivable that is recorded in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 606 (see Note 13). Other receivables include fee-for-services (“FFS”) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and based on invoices sent to the subcontracted IPA for stop loss insurance premium reimbursements. The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyses the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis. Amounts are recorded as a receivable when the Company is able to determine amounts receivable under these contracts and/or agreements based on information provided and collection is reasonably likely to occur. The Company continuously monitors its collections of receivables and its policy is to write off receivables when they are determined to be uncollectible. The Company has not incurred credit losses related to receivables. As of March 31, 2018 and December 31, 2017, the Company recorded an allowance for doubtful accounts of $ 763,205 407,953 For The Three Months 2018 2017 Payor A * % 12.9 % Payor B 12.0 % 24.0 % Payor C * % 11.9 % Payor D 10.9 % 12.7 % * Less than 10% of total net revenues The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts: As of March As of December Payor D 25.6 % 23.8 % Payor E 38.2 % 30.5 % The Company’s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, derivative asset (warrants), accounts payable, certain accrued expenses, capital lease obligations, bank loan and the line of credit. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amount of the loan receivables – long term, bank loan, capital lease obligations and line of credit approximates fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality. Fair Value Measurement This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 Level 2 Level 3 Fair Value Measurements Level 1 Level 2 Level 3 Total Assets Money market accounts* $ 42,300,818 $ - $ - $ 42,300,818 Marketable securities – certificates of deposit 1,061,022 - - 1,061,022 Marketable securities – equity securities 77,455 - - 77,455 Total $ 43,439,295 $ - $ - $ 43,439,295 The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2017 are presented below: Fair Value Measurements Level 1 Level 2 Level 3 Total Assets Money market accounts* $ 41,231,405 $ - $ - $ 41,231,405 Marketable securities – certificates of deposit 1,057,090 - - 1,057,090 Marketable securities – equity securities 86,005 - - 86,005 Total $ 42,374,500 $ - $ - $ 42,374,500 * Included in cash and cash equivalents There was no Level 3 input measured on a non-recurring basis for the three months ended March 31, 2018. Derivative Balance at January 1, 2017 $ 5,338,886 Change in fair value of warrant liabilities 1,522,222 Balance at March 31, 2017 $ 6,861,108 The fair value of the warrant derivative asset of approximately $ 6.9 3.54 4.00 1.62 1.71 62.3 62.4 9.00 0 There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the three months ended March 31, 2018 and 2017. Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate. Intangible assets with finite lives also include a patent management platform as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses and is amortized using the straight-line method. Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March 31, 2018 and 2017. Under the ASC 350, Intangibles – Goodwill and Other At least annually, at the Company’s fiscal year end, management assesses whether there has been any impairment in the value of goodwill by first comparing the fair value to the net carrying value of the reporting unit. If the carrying value exceeds its estimated fair value, a second step is performed to compute the amount of the impairment. The Company has determined it has four reporting units, which are comprised of (1) provider services, (2) management services, (3) IPA, and (4) ACO. An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances. At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances. The Company determined that there was no impairment of its goodwill during the three months ended March 31, 2018 and 2017. The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. APC, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees. APC, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income. An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. As APAACO’s NGACO program is new and not sufficient claims history is available, the medical liabilities for the NGACO program are estimated and recorded at 100 On January 1, 2018, the Company adopted the new revenue recognition standard Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings and noncontrolling interests at the date of initial application. Revenue from substantially all of the Company’s contracts with customers continues to be recognized over time as services are rendered. The 2017 comparative information has not been restated and continues to be reported under the accounting standards in effect for that period. Refer to Note 13- Revenue Recognition for further details. Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements. The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of stock-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. At times, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company’s repurchase right (but not obligation) that lapses based on performance of services in the future. The Company accounts for share-based awards granted to persons other than employees and directors under ASC 505-50 Equity-Based Payments to Non-Employees Basic earnings per share (“EPS”) is computed by dividing net income attributable to holders of the Company’s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities outstanding during the periods presented, using treasury stock method. Refer to Note 10 for a discussion of shares treated as treasury shares for accounting purposes. The basic EPS for the comparative period (the quarter ended March 31, 2017) before the closing of the Merger (see Note 3) presented in the condensed consolidated financial statements was calculated by dividing (a) by (b): a) The income of the legal acquiree (NMM) attributable to holders of the Company’s common stock in such period. b) The legal acquiree’s historical weighted average number of shares of common stock outstanding multiplied by the exchange ratio established in the Merger. The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including certain VIEs) in the Company’s consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the consolidated statements of income. Pursuant to APC’s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the condensed consolidated financial statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 and other subsequent revisions amend the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted ASU 2014-09 on January 1, 2018. Refer to Note 13. Revenue Recognition, for further details. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Topic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). ASU 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosures of financial instruments including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. The Company adopted ASU 2016-01 on January 1, 2018. The adoption of ASU 2016-01 did not have a material impact on the Company’s condensed consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Under ASU 2016-02, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 will be applied using a modified retrospective transition method and is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company does not expect to early adopt the new guidance. The Company has appointed a project team and is in the process of evaluating the impact the new standard will have on its condensed consolidated financial statements. The Company expects to complete the impact assessment process by the end of the third quarter of 2018, and to complete the implementation process, including adding procedures and evaluating necessary disclosures, prior to the end of the first quarter of 2019. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on the condensed consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). This ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The issues addressed in this ASU that will affect the Company are classifying debt prepayments or debt extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual and interim periods beginning after December 15, 2017, and interim periods within that reporting period. The Company adopted ASU 2016-15 on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact on the Company’s condensed consolidated financial statements. In December 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows (Topic 230) – Restricted Cash” (“ASU 2016-18”). The amendments in ASU 2016-18 require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-18 on January 1, 2018. As a result of adopting ASU 2016-18, the primary impact to the condensed consolidated statements of cash flows relates to including amounts generally described as restricted cash in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statements of cash flows. Also, prior period amounts in the statements of cash flows for the three months ended March 31, 2017 have been retrospectively adjusted to reflect the adoption of ASU 2016-18. In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASU 2017-01”). This ASU provides a screen to determine when a set is not a business, which requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business, which reduces the number of transactions that need to be further evaluated. If the screen is not met, this ASU requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and also remove the evaluation of whether a market participant could replace missing elements. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-01 did not have a material impact on the Company’s condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”). This ASU eliminates Step 2 from the goodwill impairment test if the carrying amount exceeds the fair value of a reporting unit and also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. This update is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on the Company’s condensed consolidated financial statements. In May 2017, the FASB issued ASU No. 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”), to clarify which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This ASU is effective for annual periods beginning after December 15, 2017. ASU 2017-09 will be applied prospectively when changes to the terms or conditions of a share-based payment award occur. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-09 did not have a material impact on the Company’s condensed consolidated financial statements. In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception” (“ASU 2017-11”). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. The amendments in Part 1 of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in any interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the impact the adoption of ASU 2017-11 will have on the Company’s condensed consolidated financial statements. With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company’s financial position, results of operations and cash flows.

Mergers and Acquisitions

Mergers and Acquisitions	3 Months Ended
	Mar. 31, 2018
Business Combinations [Abstract]
Acquisitions of non-controlling interest in BAHA	3. Mergers and Acquisitions On December 8, 2017, (the “Effective Time”) the merger (the “Merger”) of ApolloMed’s wholly-owned subsidiary, Apollo Acquisition Corp., with and into Network Medical Management, Inc. as the surviving entity was completed, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 21, 2016 (as amended on March 30, 2017 and October 17, 2017), by and among the Company, Merger Sub, NMM and Kenneth Sim, M.D., as the NMM shareholders’ representative. As a result of the Merger, NMM now is a wholly-owned subsidiary of ApolloMed and former NMM shareholders own a majority of the issued and outstanding common stock of the Company. Both companies are considered to be a business under the guidance outlined in ASC 805, Business Combinations. The combined company operates under the Apollo Medical Holdings name. NMM is the larger entity in terms of assets, revenues and earnings. In addition, as of the closing of the Merger, the majority of the board of directors of the combined company was comprised of former NMM directors and directors nominated for election by NMM. Accordingly, ApolloMed is considered to be the legal acquirer (and accounting acquiree) whereas NMM is considered to be the accounting acquirer (and legal acquiree) and, accordingly, the merger transaction is a reverse acquisition. Accordingly, as of the Effective Time, NMM’s historical results of operations replaced ApolloMed’s historical results of operations for all periods prior to the Merger, and the results of operations of both companies will be included in the Company’s financial statements for all periods following the Merger. As of the Effective Time, the Company’s board of directors approved a change in the Company’s fiscal year end from March 31 to December 31, to correspond with NMM’s fiscal year end prior to the Merger. Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of NMM common stock converted into the right to receive (i) such number of fully paid and nonassessable shares of ApolloMed’s common stock that resulted in the NMM shareholders having a right to receive an aggregate number of shares of ApolloMed’s common stock that represented 82 2,566,666 850,000 11.00 900,000 10.00 For purposes of calculating the exchange ratio, (A) the aggregate number of shares of ApolloMed common stock held by the NMM shareholders immediately following the Effective Time excluded (i) any shares of ApolloMed common stock owned by NMM shareholders immediately prior to the Effective Time, (ii) the Series A warrant and Series B warrant issued by ApolloMed to NMM to purchase ApolloMed common stock (the “ApolloMed Warrants”) and (iii) any shares of ApolloMed common stock issued or issuable to NMM shareholders pursuant to the exercise of the ApolloMed Warrants, and (B) the total number of issued and outstanding shares of ApolloMed common stock immediately following the Effective Time excluded 520,081 4.99 The consideration for the transaction was 18% of the total issued and outstanding shares of ApolloMed common stock, or 6,109,205 (immediately following the Merger). In addition, the fair value of NMM’s 50 50 5,129,000 Equity consideration (1) $ 61,092,050 Estimated fair value of ApolloMed preferred stock held by NMM (2) 19,118,000 Estimated fair value of NMM’s noncontrolling interest in APAACO (3) 5,129,000 Estimated fair value of the outstanding ApolloMed stock options (4) 187,333 Total estimated purchase consideration $ 85,526,383 (1) Equity consideration Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 The equity consideration, which represents a portion of the consideration deemed transferred to the pre-Merger ApolloMed stockholders in the Merger, is calculated based on the number of shares of the combined company that the pre-Merger ApolloMed stockholders would own as of the closing of the Merger. Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders (1) 6,109,205 Multiplied by the price per share of ApolloMed’s common stock (2) $ 10.00 Equity consideration $ 61,092,050 (1) Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger. (2) Represents the closing price of ApolloMed’s common stock on December 8, 2017. (2) Estimated fair value of ApolloMed’s preferred shares held by NMM NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger. As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed. The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A and Series B preferred stock were valued to be $ 19,118,000 2 37.9 1.8 12,745,000 6,373,000 (3) Estimated fair value of NMM’s 50% share of APA ACO Inc. Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM’s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM’s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger. (4) Estimated fair value of the ApolloMed outstanding stock options The estimated fair value of the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated with the awards. There is no future service requirement. Assets acquired Cash and cash equivalents $ 36,367,555 Accounts receivable, net 7,261,588 Other receivables 3,211,028 Prepaid expenses 249,193 Property, plant and equipment, net 1,114,332 Restricted cash 745,220 Fair value of intangible assets acquired 14,984,000 Deferred tax assets 2,301,972 Other assets 217,241 Total assets acquired $ 66,452,129 Liabilities assumed Accounts payable and accrued liabilities $ 8,632,893 Medical liabilities 39,353,540 Line of credit 25,000 Convertible note payable, net 5,376,215 Convertible note payable - related party 9,921,938 Noncontrolling interest 3,142,000 Total liabilities assumed and noncontrolling interest $ 66,451,586 Net liabilities assumed $ (913,468) Goodwill $ 85,525,840 Goodwill is not deductible for tax purposes. During the three months ended March 31, 2018, the deferred tax assets balance was increased by approximately $ 0.9 Merger from The purchase consideration and purchase price allocation are preliminary and subject to change as more information becomes available, which will be finalized as soon as practicable within the measurement period of no later than one year following the Effective Time of the Merger. MMG Transaction In conjunction with the Merger, ApolloMed sold to APC-LSMA all the issued and outstanding shares of capital stock of MMG. MMG has historically been included in the consolidated financial statements filed by ApolloMed. APC-LSMA agreed to 100 400,000 400,000 Pro Forma Combined Historical Results Three Months Net revenues $ 98,467,260 Net loss attributable to Apollo Medical Holdings, Inc. $ (351,982) Weighted average common shares outstanding: Basic 33,601,022 Earnings per share: basic $ (0.01) Weighted average common shares outstanding: diluted 33,601,022 Earnings per share: diluted $ (0.01) The pro forma information has been prepared for comparative purposes only and does not purport to be indicative of what would have occurred had the acquisition actually been made at such date, nor is it necessarily indicative of future operating results.

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	4. Intangible Assets, Net Useful Gross Net Life March 31, Accumulated March 31, (Years) 2018 Amortization 2018 Indefinite Lived Assets: Medicare license N/A $ 1,994,000 $ - $ 1,994,000 Amortized Intangible Assets: Network relationships 11-15 109,883,000 (39,179,025) 70,703,975 Management contracts 15 22,832,000 (5,646,843) 17,185,157 Member relationships 12 6,696,000 (357,292) 6,338,708 Patient management platform 5 2,060,000 (137,333) 1,922,667 Tradename/trademarks 20 1,011,000 (16,850) 994,150 $ 144,476,000 $ (45,337,343) $ 99,138,657 At December 31, 2017, the Company’s intangible assets, net, consisted of the following: Useful Gross Net Life December 31, Accumulated December 31, (Years) 2017 Amortization 2017 Indefinite Lived Assets: Medicare license N/A $ 1,994,000 $ - $ 1,994,000 Amortized Intangible Assets: Network relationships 11-15 109,883,000 (35,842,508) 74,040,492 Management contracts 15 22,832,000 (5,014,886) 17,817,114 Member relationships 12 6,696,000 (46,500) 6,649,500 Patient management platform 5 2,060,000 (34,336) 2,025,664 Tradename/trademarks 20 1,011,000 (4,212) 1,006,788 $ 144,476,000 $ (40,942,442) $ 103,533,558 Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $ 4,394,901 4,374,841 106,000 Amount 2018 (remaining nine months) $ 12,262,000 2019 14,480,000 2020 12,671,000 2021 10,961,000 2022 9,448,000 Thereafter 37,323,000 $ 97,145,000

Investments in Other Entities

Investments in Other Entities	3 Months Ended
	Mar. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]
Investments in Other Entities	5. Investments in Other Entities Equity Method Investments LaSalle Medical Associates LaSalle Medical Associates (“LMA”) was founded by Dr. Albert Arteaga in 1996 and currently operates four neighborhood medical centers employing more than 120 dedicated healthcare professionals, treating children, adults and seniors in San Bernardino County. LMA’s patients are primarily served by Medi-Cal and they also accept Blue Cross, Blue Shield, Molina, Care 1 st 5,000,000 25 (352,792) 1,311,738 9,099,975 9,452,767 Balance Sheets March 31, 2018 December 31, 2017 Assets Cash and cash equivalents $ 22,064,701 $ 21,065,105 Receivables, net 3,005,144 2,433,116 Other current assets 2,173,110 1,565,606 Loan receivable 1,250,000 1,250,000 Restricted cash 664,612 662,109 Total assets $ 29,157,567 $ 26,975,936 Liabilities and Stockholders’ Equity March 31, 2018 December 31, 2017 Current liabilities $ 23,946,133 $ 20,353,337 Stockholders’ equity 5,211,434 6,622,599 Total liabilities and stockholders’ equity $ 29,157,567 $ 26,975,936 Statements of Income March 31, 2018 March 31, 2017 Revenues $ 52,983,791 $ 49,753,004 Expenses 54,002,458 44,506,050 Net (loss) income $ (1,018,667) $ 5,246,954 Pacific Medical Imaging and Oncology Center, Inc. PMIOC was incorporated in 2004 in the state of California. PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high quality diagnostic services such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography at their facilities. In July 2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $ 1,200,000 40 APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract APC paid PMIOC fees of approximately $ 0.4 0.5 (26,025) 51,080 1,374,668 1,400,693 Universal Care, Inc. UCI is a privately held health plan that has been in operation since 1985 in order to help its members through the complexities of the healthcare system. UCI holds a license under the California Knox-Keene Health Care Services Plan Act (“Knox-Keene Act”) to operate as a full-service health plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program. On August 10, 2015, UCAP, an entity solely owned 100 100,000 48.9 50 10,000,000 (20,202) 523,301 8,589,253 8,609,455 In 2015, the Company also advanced $ 5,000,000 1 5.75 5.50 5,000,000 Balance Sheets March 31, 2018 December 31, 2017 Assets Cash $ 22,595,206 $ 21,872,894 Receivables, net 23,862,184 18,618,760 Other current assets 18,870,831 13,021,520 Other assets 2,259,507 3,754,470 Property and equipment, net 1,770,157 1,576,621 Total assets $ 69,357,885 $ 58,844,265 Liabilities and Stockholders’ Deficit March 31, 2018 December 31, 2017 Current liabilities $ 64,984,078 $ 54,421,532 Other liabilities 10,044,340 10,051,952 Stockholders’ deficit (5,670,533) (5,629,219) Total liabilities and stockholders’ deficit $ 69,357,885 $ 58,844,265 Statements of Income Operations March 31, 2018 March 31, 2017 Revenues $ 72,665,437 $ 46,540,892 Expenses 72,154,950 44,757,246 Income before provision for income taxes 510,487 1,783,646 Provision for income taxes 551,800 713,500 Net (loss) income $ (41,313) $ 1,070,146 Diagnostic Medical Group On May 14, 2016, David C.P. Chen M.D., Inc., a California professional corporation doing business as Diagnostic Medical Group (“DMG”), David C.P. Chen M.D., individually (collectively “Seller”) and APC-LSMA, a designated shareholder professional corporation formed on October 15, 2012, which is 100 40 1,600,000 APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG’s operations. APC recorded income from this investment of $ 329,042 361,644 2,176,453 1,847,411 Pacific Ambulatory Surgery Center, LLC PASC, a California limited liability company, is a multi-specialty outpatient surgery center that is certified to participate in the Medicare program and is accredited by the Accreditation Association for Ambulatory Health Care. PASC has entered into agreements with organizations such as healthcare service plans, independent physician practice associations, medical groups and other purchasers of healthcare services for the arrangement of the provision of outpatient surgery center services to subscribers or enrollees of such health plans. On November 15, 2016, PASC and APC, entered into a membership interest purchase agreement whereby PASC sold 40 800,000 In connection with the membership interest purchase agreement, PASC entered into a management services agreement with NMM, which requires the payment of management fees computed at predetermined percentage (as defined) of PASC revenues. The term of the management services agreement commenced on the effective date and extend for a period of 60 months thereafter, and may be extended in writing at the sole option of NMM for an additional period of 60 months following the expiration of the initial term and is automatically renewed for additional consecutive terms of three years unless terminated by either party. PASC shall not be permitted to terminate the management services agreement for any reason during the initial term and, if extended, the extended term. APC accounts for its investment in PASC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PASC’s operations. APC recorded income (loss) from this investment of $ 41,953 (20,501) 635,151 593,198 Equity Method Investment Summary March 31, 2018 December 31, 2017 Universal Care, Inc. $ 8,589,253 $ 8,609,455 LaSalle Medical Associates – IPA Line of Business 9,099,975 9,452,767 Diagnostic Medical Group 2,176,453 1,847,411 Pacific Medical Imaging & Oncology Center, Inc. 1,374,668 1,400,693 Pacific Ambulatory Surgery Center, LLC 635,151 593,198 $ 21,875,500 $ 21,903,524

Loan Receivable

Loan Receivable	3 Months Ended
	Mar. 31, 2018
Loan Receivable [Abstract]
Loan Receivable	6. Loan Receivable On October 9, 2017, NMM and APC-LSMA entered into an agreement with Accountable Health Care IPA (“Accountable”), a California professional medical corporation, Signal Health Solutions, Inc. (“Signal”), a California corporation and George M. Jayatilaka, M.D. (“Dr. Jay”), individually, whereby concurrent with the execution of the agreement, APC-LSMA extended a line of credit to Dr. Jay in the principal amount of $ 10,000,000 5,000,000 5,000,000 prime rate plus 1% 5.75 5.50 Concurrently with the funding of the Dr. Jay Loan, Dr. Jay will loan to Accountable the entire proceeds of the Dr. Jay Loan at the same interest rate and maturity date as the Dr. Jay Loan (“Dr. Jay-Accountable Subordinated Loan”). Repayment of the Dr. Jay-Accountable Subordinated Loan will be subordinated to Accountable’s creditors in a manner acceptable to the California Department of Managed Health Care (“DMHC”). At any time on or before the date that is one year following the initial funding date of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert up to $5,000,000 of the outstanding principal amount into shares of Accountable’s capital stock. At any time after the date that is one year following the funding date, the Dr. Jay Loan may be prepaid at any time. Within three years following the initial funding of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert the then outstanding principal amount into Accountable shares based on Accountable’s then-current valuation. Subsequent to the funding of the Dr. Jay Loan, to the extent needed by Accountable for working capital needs as determined by APC-LSMA, APC-LSMA will extend an additional line of credit in the principal amount up to $ 8,000,000 As a condition of funding the Dr. Jay Loan, Accountable entered into a management service agreement with NMM on October 27, 2017, to commence on the termination of the Accountable’s existing management agreement with MedPoint Management to be effective on December 1, 2017 and have a term of ten (10) years from its effective date. NMM will be responsible for managing 100 Concurrent with the initial funding of the Dr. Jay Loan, the Accountable Board of Directors shall be automatically reconstituted to be comprised of two directors, which will comprise of Dr. Jay and a director appointed by APC-LSMA. Dr. Jay and APC-LSMA will have two and one votes as a director, respectively. Based on management’s assessment, Accountable is a variable interest entity, however, the Company does not have the power to the direct the activities of Accountable that most significantly impact its economic performance and as such, the Company is not the primary beneficiary of Accountable.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	7. Accounts Payable and Accrued Expenses March 31, 2018 December 31, 2017 Accounts payable $ 3,356,677 $ 3,786,381 Specialty capitation payable 300,000 547,307 Subcontractor IPA risk pool payable 1,472,985 1,348,376 Professional fees 2,727,238 3,004,215 Deferred revenue 710,106 250,000 Accrued compensation 3,543,524 4,343,341 $ 12,110,530 $ 13,279,620

Medical Liabilities

Medical Liabilities	3 Months Ended
	Mar. 31, 2018
Disclosure of Medical Liabilities [Abstract]
Medical Liabilities	8. Medical Liabilities March 31, 2018 December 31, 2017 Balance, beginning of period $ 63,972,318 $ 18,957,465 Medical liabilities assumed from Merger - 39,353,540 Claims paid for previous period (28,633,287) (23,075,516) Incurred health care costs 44,634,257 121,846,375 Claims paid for current period (10,805,984) (92,476,160) Adjustments (56,478) (633,386) Balance, end of period $ 69,110,826 $ 63,972,318

Bank Loan, Lines of Credit and

Bank Loan, Lines of Credit and Loan Payable – Related Party	3 Months Ended
	Mar. 31, 2018
Disclosure of Bank Loan, Lines of Credit and Loan Payable - Related Party [Abstract]
Bank Loan Lines Of Credit And Loan Payable Related Party	9. Bank Loan, Lines of Credit and Loan Payable – Related Party Bank Loans In December 2010, ICC borrowed $ 4,600,000 4.75 4.50 December 31, 2018 394,783 510,391 Lines of Credit In April 2012, NMM entered into a promissory note agreement with a bank, which was amended on April 9, 2016 and April 7, 2017 (as amended, the “NMM Business Loan Agreement”). The NMM Business Loan Agreement was amended on April 7, 2017 to increase the loan availability from $ 10,000,000 20,000,000 “prime rate” plus 0.125% 4.875 4.675 1,000,000 5,000,000 April 22, 2018 June 22, 2018 5,000,000 8,300,671 In April 2012, APC entered into a promissory note agreement with a bank, which was amended on April 22, 2016 and April 7, 2017 (as amended, the “APC Business Loan Agreement”). The APC Business Loan Agreement modifies certain terms of the promissory note agreement in order to (i) increase the original loan availability amount of $ 2,000,000 10,000,000 4.875 4.675 1,000,000 9,694,984 Standby Letters of Credit On March 3, 2017, APAACO established an irrevocable standby letter of credit with a financial institution (through the NMM Business Loan Agreement) for $ 6,699,329 The letter of credit expires on December 31, 2018 and deemed automatically extended without amendment for additional one - year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date. APC established irrevocable standby letters of credit with a financial institution for a total of $ 305,016

Mezzanine and Stockholders_ Equ

Mezzanine and Stockholders’ Equity	3 Months Ended
	Mar. 31, 2018
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	10. Mezzanine and Stockholders’ Equity All the historical NMM share and per share information has been adjusted to reflect the exchange ratio from the Merger (see Note 3). Mezzanine APC As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interests in mezzanine or temporary equity. Stockholders’ Equity As of the date of this Quarterly Report on Form 10-Q, 1,000,970 3,039,749 On March 21, 2018, the Company issued 37,593 16.80 631,562 See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants. Options Shares Weighted Weighted Aggregate Options outstanding at January 1, 2018 1,141,040 $ 3.95 5.79 $ 19.81 Options granted 30,000 9.25 - - Options exercised (129,536) 6.11 - 15.03 Options forfeited - - - - Options outstanding at March 31, 2018 1,041,504 $ 4.09 5.66 $ 11.86 Options exercisable at March 31, 2018 1,041,504 $ 4.09 5.66 $ 11.86 During the quarter ended March 31, 2018, stock options were exercised pursuant to the cashless exercise provision of the option agreement, with respect to 54,536 43,201 During the quarter ended March 31, 2018, stock options were exercised for 75,000 479,000 2.10 10.00 Shares Weighted Weighted Aggregate Options outstanding at January 1, 2018 853,800 $ 0.167 1.75 $ 508,864 Options granted - - - - Options exercised - - - - Options expired/forfeited - - - - Options outstanding at March 31, 2018 853,800 $ 0.167 1.50 $ 508,864 Options exercisable at March 31, 2018 853,800 $ 0.167 1.50 $ 508,864 The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of common stock as of March 31, 2018. Three Months Ended March 31, 2018 2017 Contracted physicians and other services $ 202,382 $ 321,233 The remaining unrecognized share-based compensation expense of stock option awards granted to primary care physicians to purchase shares of APC’s common stock as of March 31, 2018 was $ 1,214,292 1.50 Warrants Shares Weighted Weighted Aggregate Warrants outstanding at January 1, 2017 3,648,541 $ 9.75 3.74 $ 14.25 Warrants granted - - - - Warrants exercised (191,625) 7.55 - 9.96 Warrants expired/forfeited (11,250) - - - Warrants outstanding at March 31, 2018 3,445,666 $ 9.88 3.69 $ 6.07 Weighted Weighted Average Average Exercise Price Exercise Price Per Warrants Remaining Warrants Per Share Outstanding Contractual Life Exercisable Share $ 4.50 24,000 0.60 24,000 $ 4.50 9.00 1,116,111 2.53 1,116,111 9.00 10.00 1,455,555 4.05 1,455,555 10.00 11.00 850,000 4.69 850,000 11.00 $ 4.50 –11.00 3,445,666 3.69 3,445,666 $ 9.88 During the quarter ended March 31, 2018, common stock warrants were exercised for 191,625 1.4 4.00 10.00 Treasury Stock APC owns 1,682,110

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Regulatory Matters Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medi-Cal programs. As risk-bearing organizations, APC and MMG are required to follow regulations of the DMHC, including maintenance of minimum working capital, tangible net equity (“TNE”), cash-to-claims ratio and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. At March 31, 2018 and December 31, 2017, APC was in compliance with these regulations. At March 31, 2018 and December 31, 2017, MMG was not in compliance with these regulations. As a result, the California DMHC required MMG to develop and implement a corrective action plan (“CAP”) for such deficiency. The Company has been in communication with the DMHC regarding MMG’s business plans that, if implemented, could result in a significant reduction in the health plan enrollment assigned to MMG. MMG received confirmation from substantially all of MMG’s direct-contracted health plans, that they have moved membership out of MMG effective May 1, 2018. MMG is currently working with DMHC on providing a CAP plan. Many of the Company’s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations. Litigation From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company’s financial condition, cash flows or results of operations. On or about March 23, 2018 and April 3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and Prospect Medical Systems, Inc. (collectively, “Prospect”) against MMG, ApolloMed and AMM with Judicial Arbitration Mediation Services (“JAMS”), arising out of MMG’s purported business plans, seeking damages in excess of $ 5

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	12. Related Party Transactions On November 16, 2015, APC entered into a subordinated note receivable agreement with UCI, a 48.9 5,000,000 During the three months ended March 31, 2018 and 2017, APC paid approximately $ 22,000 34,000 During the three months ended March 31, 2018 and 2017, NMM received approximately $ 4.6 4.5 25 During the three months ended March 31, 2018 and 2017, APC paid approximately $ 0.4 0.5 40 During the three months ended March 31, 2018 and 2017, APC paid approximately $ 0.7 0.8 In September 2015, ApolloMed entered into a note receivable with Rob Mikitarian, a minority owner in APS, in the amount of approximately $ 150,000 3 150,000 In addition, affiliates wholly-owned by the Company’s officers, including Dr. Lam and Dr. Hosseinion, are reported in the accompanying consolidated statement of income on a consolidated basis, together with the Company’s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company’s subsidiaries as related party transactions. During the three months ended March 31, 2018 and 2017, APC paid approximately $ 1.6 1.4 40 During the three months ended March 31, 2018 and 2017, NMM paid approximately $ 0.3 During the three months ended March 31, 2018 and 2017, APC paid approximately $ 90,000 During the three months ended March 31, 2018 and 2017, APC paid an aggregate of approximately $ 9.2 12.8 2.3 5.4 For loans receivable from related parties, see Note 6.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition At the adoption of Topic 606, the majority of what was previously classified as the provision for bad debts in the consolidated statements of income is now reflected as implicit price concessions and, therefore, included as a reduction to revenues starting in 2018. For changes in credit issues not assessed at the date of service, the Company will prospectively recognize those amounts in operating expenses in the condensed consolidated statements of income. In addition, the cumulative effect of initially applying the new revenue standard is required to be presented as an adjustment to the opening balance of retained earnings. This cumulative effect amount was determined to be related to the full risk pool arrangements of APC, a variable interest entity (see Note 1). Therefore, the cumulative net effect of initially applying Topic 606 in the amount of $ 10,208,000 11,600,000 1,392,000 1,392,000 3,246,098 The adoption of this ASU did not have a significant impact on the Company’s revenue, when comparing the amount of revenue recognized for the three months ended March 31, 2018 to the revenue that would have been recognized under the prior revenue standard ASC 605, such that comparisons of revenues and operating profit performance between periods are not affected by the adoption of this ASU. Balance at Adjustments Balance at Current Assets Receivables $ 20,117,304 $ 11,600,000 $ 31,717,304 Liabilities, Mezzanine Equity and Stockholders’ Equity Noncurrent Liabilities Deferred tax liability $ 24,916,598 $ 3,246,098 $ 28,162,696 Mezzanine equity Noncontrolling interest in Allied Pacific of California IPA $ 172,129,744 $ 7,351,434 $ 179,481,178 Stockholders’ Equity Retained earnings $ 1,734,531 $ 1,002,468 $ 2,736,999 The Company operates as one reportable segment, the healthcare delivery segment. The Company disaggregates revenue from contracts by service type and by payor. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. March 31, 2018 March 31, 2017 Commercial $ 105,350,102 $ 83,848,918 Medicare 18,541,115 1,453,703 Medicaid 176,350 - Other third parties 99,160 33,441 Revenue $ 124,166,727 $ 85,336,062 The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third party payors (e.g., hospitals); and (v) individual patients and clients. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component. The Company derives a significant portion of its revenue from Medicare, Medicaid and other payors that receive discounts from established billing rates. The Medicare and Medicaid regulations and various managed care contracts under which these discounts must be calculated are complex, subject to interpretation and adjustment, and may include multiple reimbursement mechanisms for different types of services provided and cost settlement provisions. Management estimates the transaction price on a payor-specific basis given its interpretation of the applicable regulations or contract terms. The services authorized and provided and related reimbursements are often subject to interpretation that could result in payments that differ from the Company’s estimates. Additionally, updated regulations and contract renegotiations occur frequently, necessitating regular review and assessment of the estimation process by management. Settlements under cost reimbursement agreements with third-party payors are estimated and recorded in the period in which the related services are rendered and are adjusted in future periods as final settlements are determined. Final determination of amounts earned under the Medicare and Medicaid programs often occurs in subsequent years because of audits by such programs, rights of appeal and the application of numerous technical provisions. Under the new revenue standard, the Company has elected to apply the following practical expedients and optional exemptions: · Recognize incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred. These costs are recorded within general and administrative expenses. · Recognize revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company’s services completed to date. · Exemptions from disclosing the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which revenue is recognized in the amount of consideration to which the Company has a right to invoice for services performed, and (iii) contracts for which variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct service that forms part of a single performance obligation. · Use a portfolio approach for the fee-for-service (FFS) revenue stream to group contracts with similar characteristics and analyze historical cash collections trends. · No adjustment is made for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less. Nature of Services and Revenue Streams Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (“AIPBP”) revenue, management fee income, MSSP surplus revenue and FFS revenue. Revenue is recorded in the period in which services are rendered. The form of billing and related risk of collection for such services may vary by type of revenue and the customer. The following is a summary of the principal forms of the Company’s billing arrangements and how revenue is recognized for each. Capitation, net Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under either provider service agreements (each, a “PSA”) or capitated arrangements directly made with various managed care providers including HMOs. Capitation revenue under the PSAs and HMO contracts is prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services. Minor ongoing adjustments to prior months’ capitation, primarily arising from contracted HMOs finalizing of monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a “Risk Adjustment model,” which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company. Per member per month (PMPM) managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes per member per month fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company’s net PMPM transaction price relates specifically to its efforts to transfer the service for a distinct increment of the series (e.g. day or month) and is recognized as revenue in the month in which members are entitled to service. Risk Pool Settlements and Incentives APC and APAACO enter into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC and APAACO is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC and APAACO generally receives a percentage of the net surplus from the affiliated hospital’s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. Risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for IBNR completion factor and constraint percentages were used by management in applying the most likely method. Under capitated arrangements with certain HMOs, APC and APAACO participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC and APAACO is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished. Risk pool settlements under arrangements with HMOs are recognized using the most likely methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year. As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR, risk adjustment factors, stop loss provisions, etc., an estimate cannot be developed. Due to these limitations, APAACO In addition to risk-sharing revenues, the Company also receives incentives under “pay-for-performance” programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed the quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for efforts it takes to improve the quality of services and for efficient and effective use of pharmacy supplemental benefits provided to the HMO’s members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. Incentives under “pay-for-performance” programs are recognized using the most likely methodology. As the Company does not have sufficient insight from the health plans on the amount and timing of the incentive payments, this revenue is considered to be fully constrained and is only recorded when such payments are received. Generally for the foregoing arrangements, the final settlement is dependent on each distinct day’s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e. the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained. NGACO AIPBP Revenue Under the NGACO Model, CMS grants the Company a pool of patients to manage (direct care and pay providers) based on a budget established with CMS. The Company is responsible for managing medical costs for these patients. The patients will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed or paid by CMS and the Company’s profits or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company’s risk share agreement with CMS, the Company will be eligible to receive the surplus or be liable for the deficit according to the budget established by CMS based on the Company’s efficiency or lack thereof, respectively, in managing how the patients assigned to the Company by CMS are served by in-network and out-of-network providers. The Company’s profits or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. In accordance with the guidance in ASC 606-10-55-36 through 55-40 on principal versus agent considerations, the Company records such revenues in the gross amount of consideration. The Company also has arrangements for billing and payment services with the medical providers within the NGACO network. The Company retains certain defined percentages of the payments made to the providers in exchange for using the Company’s billing and payment services. The revenue for this service is earned as payments are made to medical providers. APAACO and CMS entered into a Next Generation ACO Model Participation Agreement (the “Participation Agreement”) with a term of two performance years through December 31, 2018. CMS may offer to renew the Participation Agreement for additional terms of two performance years. For each performance year, the Company shall submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year. For each performance year, CMS shall pay the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies owed. If CMS owes the Company shared savings or other monies owed, CMS shall pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company shall pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS shall assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company. The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO’s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients. As it relates specifically to the Company’s Participation Agreement with CMS, the Company recognizes capitation revenue in the month in which the Company is obligated to provide services. Also, because the Company’s arrangement with CMS is new (became effective in 2017), numerous factors create uncertainty regarding the risk pool settlement and incentive amounts that the Company is entitled to receive and limited historical data exists to develop reasonable and reliable estimates. As a result, the Company recognizes revenue from risk pool settlements and incentives under the arrangement with CMS in the period in which amounts are estimable and collection is reasonably assured. The Company will continue to evaluate and assess the reliability and reasonableness of data available to it in order develop future estimates, and will recognize risk pool settlements and incentives revenue based on such estimates only to the extent it is probable that a significant reversal of cumulative revenue will not occur in future periods. In October 2017, CMS notified the Company that it would not be renewed for participation in the AIPBP payment mechanism of the NGACO Model for performance year 2018 due to certain alleged deficiencies in performance. The Company submitted a reconsideration request. In December 2017, the Company received the official decision on its reconsideration request that CMS reversed the prior decision against the Company’s continued participation in the AIPBP mechanism. As a result, the Company is eligible for receiving monthly AIPBP payments currently at a rate of approximately $ 7.3 Management Fee Income Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. Such variable supplemental revenues are recognized as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the respective agreement. The Company’s MSA revenue also includes revenue sharing payments from the Company’s partners based on their non-medical services. The Company provides a significant service of integrating the services selected by the Company’s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company’s performance obligation is to stand ready to provide services over the contractual period. Also, the Company’s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company’s performance obligation is satisfied as the Company completes each period’s obligations. Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company’s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company’s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled. The Company’s management contracts generally have long terms (e.g., ten years), although they may be terminated earlier under the terms of the respective contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations. Medicare Shared Savings Program Surplus Revenue The Company participates in the MSSP, which is sponsored by CMS. The goal of the MSSP is to improve the quality of patient care and outcomes through a more efficient and coordinated approach among providers. The MSSP allows ACO participants to share in cost savings it generates in connection with rendering medical services to Medicare patients. Payments to ACO participants, if any, will be calculated annually by CMS on cost savings generated by the ACO participant relative to the ACO participants’ cost savings benchmark. Revenues earned by the Company are uncertain, and, if such amounts are payable by CMS, they will be paid on an annual basis significantly after the time earned, and will be contingent on various factors, including achievement of the minimum savings rate as determined by MSSP for the relevant period. Such payments are earned and made on an “all or nothing” basis. The Company considers revenue, if any, under the MSSP, as contingent upon the realization of program savings as determined solely by CMS, which are subject to significant estimation risk. Accordingly, they are not recognized as revenue until the amounts are estimable and collection is reasonably assured, which is generally when notice is received from CMS that cash payments are to be imminently received. Fee-for-Service Revenue FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company’s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company’s billing center for medical coding and entering into the Company’s billing system and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company’s billing systems as well as an estimate of the revenue associated with medical services. The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company’s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues. Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period. Contract Assets Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company’s contract assets comprise accounts receivable. Generally, the Company does not have material amounts of other contract assets. Contract Liabilities (Deferred Revenue Contract liabilities are recorded when cash payments are received in advance of the Company’s performance, which is generally uncommon. The Company’s contract liability balance was $ 710,106 250,000

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes On December 22, 2017, the U.S. government enacted comprehensive tax legislation known as the Tax Cuts and Jobs Act (the “TCJA”). The TCJA establishes new tax laws that will take effect in 2018, including, but not limited to (1) a reduction of the U.S. federal corporate tax rate from a maximum of 35 21 80 ASC 740, Income Taxes, generally requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the TCJA’s provisions, the SEC staff issued Staff Accounting Bulletin 118 (“SAB 118”), which provides guidance on accounting for the tax effects of the TCJA. SAB 118 provides a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the TCJA for which the accounting under ASC 740 is complete. To the extent that a company’s accounting for certain income tax effects of the TCJA is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provisions of the tax laws that were in effect immediately before the enactment of the TCJA. At March 31, 2018 and December 31, 2017, the Company did not complete its accounting for the tax effects of enactment of the TCJA; however, the Company has made a reasonable estimate of the effects of the TCJA’s change in the federal rate and revalued its deferred tax assets based on the rates at which they are expected to reverse in the future, which is generally the new 21% federal corporate tax rate plus applicable state tax rate. The Company recorded a decrease in its deferred tax assets and deferred tax liabilities of $ 6.6 16.3 9.7 On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision (benefit) in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company’s estimated effective tax rate. If and when this occurs, the income tax provision (benefit) will be adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company’s deferred taxes and related valuation allowance, may create fluctuations in the Company’s overall effective tax rate from quarter to quarter. As of March 31, 2018, due to overall cumulative losses incurred, prior to the merger with NMM, in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the Federal consolidation rules, as realization of these assets is uncertain. The Company’s effective tax rate for the three months ended March 31, 2018 differed from the U.S. federal statutory rate primarily due to state income taxes. As of March 31, 2018, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense. The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries’ state and Federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2013 through December 31, 2016 and for the years ended December 31, 2014 through December 31, 2016, respectively. The Company currently does not anticipate material unrecognized tax benefits within the next 12 months.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share	15. Earnings Per Share Basic net income per share is calculated using the weighted average number of shares of the Company’s common stock issued and outstanding during a certain period, and is calculated by dividing net income by the weighted average number of shares of the Company’s common stock issued and outstanding during such period. Diluted net income per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants. Pursuant to the Merger Agreement, ApolloMed held back 10% of the shares of its common stock that were issuable to NMM shareholders (“Holdback Shares”) to secure indemnification of ApolloMed and its affiliates under the Merger Agreement. The Holdback Shares will be held for a period of up to 24 months after the closing of the Merger (to be distributed on a pro-rata basis to former NMM shareholders), during which ApolloMed may seek indemnification for any breach of, or noncompliance with, any provision of the Merger Agreement, by NMM. The Holdback Shares are excluded from the computation of basic earnings per share, but included in diluted earnings per share. As of both March 31, 2018 and 2017, APC held 1,682,110 Three Months Ended March 31, 2018 2017 Earnings per share – basic $ 0.07 $ 0.17 Earnings per share – diluted $ 0.06 $ 0.15 Weighted average shares of common stock outstanding – basic 32,421,467 25,067,954 Weighted average shares of common stock outstanding – diluted 38,098,373 28,445,647 Three Months Ended March 31, 2018 2017 Weighted average shares of common stock outstanding – basic 32,421,467 25,067,954 10% shares held back pursuant to indemnification clause 3,039,749 2,785,328 Stock options 835,790 592,365 Warrants 1,801,367 - Weighted average shares of common stock outstanding – diluted 38,098,373 28,445,647

Variable Interest Entities (VIE

Variable Interest Entities (VIEs)	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
VIE Assets	Variable Interest Entities (VIEs) A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity’s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE. The Company’s VIEs include APC and other immaterial entities. Assets recognized as a result of consolidating these VIEs do not represent additional assets that could be used to satisfy claims against the Company’s general assets. Conversely, liabilities recognized as a result of consolidating these VIEs do not represent additional claims on the Company’s general assets; rather, they represent claims against the specific assets of the VIE. The Company evaluates its relationships with its VIEs on an ongoing basis to ensure that it continues to be the primary beneficiary. March 31, December 31, Assets Current assets Cash and cash equivalents $ 58,024,188 $ 54,686,370 Restricted cash – short-term 18,028,116 18,005,661 Fiduciary cash 1,386,474 2,017,437 Investment in marketable securities 1,061,022 1,057,090 Receivables, net 38,844,184 15,183,483 Prepaid expenses and other current assets 1,960,737 1,821,328 Total current assets 119,304,721 92,771,369 Noncurrent assets Land, property and equipment, net 10,201,045 10,167,689 Intangible assets, net 67,670,837 70,841,907 Goodwill 60,012,316 60,012,316 Loans receivable – related parties 5,000,000 5,000,000 Loan receivable 5,000,000 5,000,000 Investments in other entities – equity method 21,875,500 21,903,524 Investments in other entities – cost method 4,320,000 4,320,000 Restricted cash – long-term 745,293 745,235 Other assets 1,155,114 1,371,664 Total noncurrent assets 175,980,105 179,362,335 Total assets $ 295,284,826 $ 272,133,704 Current liabilities Accounts payable and accrued expenses $ 3,505,047 $ 3,625,610 Incentives payable 14,900,000 21,500,000 Fiduciary accounts payable 1,386,474 2,017,437 Medical liabilities 25,212,116 25,186,240 Income taxes payable 3,229,058 1,463,540 Amount due to affiliate 28,061,953 24,889,717 Bank loan, short-term 394,783 510,391 Capital lease obligations 99,480 98,738 Total current liabilities 76,788,911 79,291,673 Noncurrent liabilities Deferred tax liability 27,406,818 20,970,766 Liability for unissued equity shares 1,185,025 1,185,025 Capital lease obligations, net of current portion 593,852 619,001 Total noncurrent liabilities 29,185,695 22,774,792 Total liabilities $ 105,974,606 $ 102,066,465 The assets of the Company’s other consolidated VIEs were not considered significant. Approximately $ 18,000,000

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events In April 2018, NMM distributed approximately $ 10,000,000 8,000,000 In April 2018, APC acquired a 50 109,000 89,000

Basis of Presentation and Sum23

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated balance sheet at December 31, 2017, has been derived from audited consolidated financial statements but do not include all disclosures required by accounting principles generally accepted in the United States of America (“U.S. GAAP”). The accompanying unaudited condensed consolidated financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the U.S. Securities and Exchange Commission (“SEC”) on April 2, 2018. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made in the condensed consolidated financial statements. The condensed consolidated financial statements include all material adjustments (consisting of normal recurring accruals) necessary to make the condensed consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. The Company’s quarterly results fluctuate. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018 or any future periods.
Principles of Consolidation	Principles of Consolidation The condensed consolidated balance sheets as of December 31, 2017 and March 31, 2018, includes the accounts of ApolloMed, its consolidated subsidiaries NMM, including NMM’s subsidiaries, APCN-ACO and AP-ACO, AMM, APAACO and Apollo Care Connect, NMM’s consolidated VIE, APC, APC’s subsidiary, UCAP, and APC’s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2017, includes NMM, its consolidated VIE, APC, APC’s subsidiary, UCAP, and APC’s consolidated VIEs, CDSC, APC-LSMA and ICC. The condensed consolidated statement of income for the three months ended March 31, 2018, includes ApolloMed, its consolidated subsidiaries NMM, AMM, APAACO and Apollo Care Connect, NMM’s consolidated VIE, APC, APC’s subsidiary, UCAP, and APC’s consolidated VIEs, CDSC, APC-LSMA and ICC. All material intercompany balances and transactions have been eliminated in consolidation.
Business Combinations	Business Combinations The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.
Reportable Segments	Reportable Segments The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative health care models to create a patient-centered, physician-centric experience. The Company reports its condensed consolidated financial statements in the aggregate, including all activities in one reportable segment.
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (including incurred, but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivable (including constraints, completion factors and the modified retrospective adjustments), income taxes and valuation of share-based compensation. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.
Reclassifications	Reclassifications Certain amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on the Company’s reported revenue, net income, cash flows or total assets.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company’s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents. The Company maintains its cash in deposit accounts with several banks, which at times may exceed the Federal Deposit Insurance Corporation (“FDIC”)’s insured limits. The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of March 31, 2018, the Company’s deposit accounts with banks exceeded the FDIC’s insured limit by approximately $ 135.0
Restricted Cash	Restricted Cash At times, APC is required to maintain a reserve fund by certain health plans, which are held in certificate of deposit accounts with initial maturities of six months from the date of purchase and interest rates ranging from 0.05 0.10 18,028,116 18,005,661 18,000,000
Receivables	Receivables The Company’s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool, incentive receivables and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected. Capitation and claims receivable relate to the health plan’s capitation, which is received by the Company in the following month of service. Risk pool and incentive receivables mainly consist of the Company’s full risk pool receivable that is recorded in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 606 (see Note 13). Other receivables include fee-for-services (“FFS”) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and based on invoices sent to the subcontracted IPA for stop loss insurance premium reimbursements. The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyses the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis. Amounts are recorded as a receivable when the Company is able to determine amounts receivable under these contracts and/or agreements based on information provided and collection is reasonably likely to occur. The Company continuously monitors its collections of receivables and its policy is to write off receivables when they are determined to be uncollectible. The Company has not incurred credit losses related to receivables. As of March 31, 2018 and December 31, 2017, the Company recorded an allowance for doubtful accounts of $ 763,205 407,953
Concentrations of Risks	Concentrations of Risks For The Three Months 2018 2017 Payor A * % 12.9 % Payor B 12.0 % 24.0 % Payor C * % 11.9 % Payor D 10.9 % 12.7 % * Less than 10% of total net revenues The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts: As of March As of December Payor D 25.6 % 23.8 % Payor E 38.2 % 30.5 %
Fair Value Measurements of Financial Instruments	Fair Value Measurements of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, derivative asset (warrants), accounts payable, certain accrued expenses, capital lease obligations, bank loan and the line of credit. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amount of the loan receivables – long term, bank loan, capital lease obligations and line of credit approximates fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality. FASB ASC 820, Fair Value Measurement This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 Level 2 Level 3 Fair Value Measurements Level 1 Level 2 Level 3 Total Assets Money market accounts* $ 42,300,818 $ - $ - $ 42,300,818 Marketable securities – certificates of deposit 1,061,022 - - 1,061,022 Marketable securities – equity securities 77,455 - - 77,455 Total $ 43,439,295 $ - $ - $ 43,439,295 The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2017 are presented below: Fair Value Measurements Level 1 Level 2 Level 3 Total Assets Money market accounts* $ 41,231,405 $ - $ - $ 41,231,405 Marketable securities – certificates of deposit 1,057,090 - - 1,057,090 Marketable securities – equity securities 86,005 - - 86,005 Total $ 42,374,500 $ - $ - $ 42,374,500 * Included in cash and cash equivalents There was no Level 3 input measured on a non-recurring basis for the three months ended March 31, 2018. Derivative Balance at January 1, 2017 $ 5,338,886 Change in fair value of warrant liabilities 1,522,222 Balance at March 31, 2017 $ 6,861,108 The fair value of the warrant derivative asset of approximately $ 6.9 3.54 4.00 1.62 1.71 62.3 62.4 9.00 0 There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the three months ended March 31, 2018 and 2017.
Intangible Assets and Long-Lived Assets	Intangible Assets and Long-Lived Assets Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate. Intangible assets with finite lives also include a patent management platform as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses and is amortized using the straight-line method. Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the three months ended March 31, 2018 and 2017.
Goodwill and Indefinite-Lived Intangible Assets	Goodwill and Indefinite-Lived Intangible Assets Under the ASC 350, Intangibles – Goodwill and Other At least annually, at the Company’s fiscal year end, management assesses whether there has been any impairment in the value of goodwill by first comparing the fair value to the net carrying value of the reporting unit. If the carrying value exceeds its estimated fair value, a second step is performed to compute the amount of the impairment. The Company has determined it has four reporting units, which are comprised of (1) provider services, (2) management services, (3) IPA, and (4) ACO. An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances. At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances. The Company determined that there was no impairment of its goodwill during the three months ended March 31, 2018 and 2017.
Investments in Other Entities	Investments in Other Entities - Equity Method The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate.
Medical Liabilities	Medical Liabilities APC, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to its enrollees. APC, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income. An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. As APAACO’s NGACO program is new and not sufficient claims history is available, the medical liabilities for the NGACO program are estimated and recorded at 100
Revenue Recognition	Revenue Recognition On January 1, 2018, the Company adopted the new revenue recognition standard Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings and noncontrolling interests at the date of initial application. Revenue from substantially all of the Company’s contracts with customers continues to be recognized over time as services are rendered. The 2017 comparative information has not been restated and continues to be reported under the accounting standards in effect for that period. Refer to Note 13- Revenue Recognition for further details.
Income Taxes	Income Taxes Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the financial statements.
Stock-Based Compensation	Share-Based Compensation The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of stock-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting terms of the awards, adjusted for expected forfeitures. At times, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company’s repurchase right (but not obligation) that lapses based on performance of services in the future. The Company accounts for share-based awards granted to persons other than employees and directors under ASC 505-50 Equity-Based Payments to Non-Employees
Basic and Diluted Earnings Per Share	Basic and Diluted Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income attributable to holders of the Company’s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities outstanding during the periods presented, using treasury stock method. Refer to Note 10 for a discussion of shares treated as treasury shares for accounting purposes. The basic EPS for the comparative period (the quarter ended March 31, 2017) before the closing of the Merger (see Note 3) presented in the condensed consolidated financial statements was calculated by dividing (a) by (b): a) The income of the legal acquiree (NMM) attributable to holders of the Company’s common stock in such period. b) The legal acquiree’s historical weighted average number of shares of common stock outstanding multiplied by the exchange ratio established in the Merger.
Non-controlling Interests	Noncontrolling Interests The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including certain VIEs) in the Company’s consolidated entities. The amount of net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.
Mezzanine Equity	Mezzanine Equity Pursuant to APC’s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the condensed consolidated financial statements.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 and other subsequent revisions amend the guidance for revenue recognition to replace numerous, industry specific requirements and converges areas under this topic with those of the International Financial Reporting Standards. The ASU implements a five-step process for customer contract revenue recognition that focuses on transfer of control, as opposed to transfer of risk and rewards. The amendment also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenues and cash flows from contracts with customers. Other major provisions include the capitalization and amortization of certain contract costs, ensuring the time value of money is considered in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company adopted ASU 2014-09 on January 1, 2018. Refer to Note 13. Revenue Recognition, for further details. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Topic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities” (“ASU 2016-01”). ASU 2016-01 addresses certain aspects of recognition, measurement, presentation and disclosures of financial instruments including the requirement to measure certain equity investments at fair value with changes in fair value recognized in net income. The Company adopted ASU 2016-01 on January 1, 2018. The adoption of ASU 2016-01 did not have a material impact on the Company’s condensed consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Under ASU 2016-02, lessees will be required to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 will be applied using a modified retrospective transition method and is effective for the Company in the first quarter of 2019, with early adoption permitted. The Company does not expect to early adopt the new guidance. The Company has appointed a project team and is in the process of evaluating the impact the new standard will have on its condensed consolidated financial statements. The Company expects to complete the impact assessment process by the end of the third quarter of 2018, and to complete the implementation process, including adding procedures and evaluating necessary disclosures, prior to the end of the first quarter of 2019. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will become effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact ASU 2016-13 will have on the condensed consolidated financial statements. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) – Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016-15”). This ASU provides clarification regarding how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The issues addressed in this ASU that will affect the Company are classifying debt prepayments or debt extinguishment costs and contingent consideration payments made after a business combination. This update is effective for annual and interim periods beginning after December 15, 2017, and interim periods within that reporting period. The Company adopted ASU 2016-15 on January 1, 2018. The adoption of ASU 2016-15 did not have a material impact on the Company’s condensed consolidated financial statements. In December 2016, the FASB issued ASU No. 2016-18, “Statement of Cash Flows (Topic 230) – Restricted Cash” (“ASU 2016-18”). The amendments in ASU 2016-18 require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-18 on January 1, 2018. As a result of adopting ASU 2016-18, the primary impact to the condensed consolidated statements of cash flows relates to including amounts generally described as restricted cash in cash and cash equivalents when reconciling beginning-of-period and end-of-period total amounts shown on the statements of cash flows. Also, prior period amounts in the statements of cash flows for the three months ended March 31, 2017 have been retrospectively adjusted to reflect the adoption of ASU 2016-18. In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASU 2017-01”). This ASU provides a screen to determine when a set is not a business, which requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business, which reduces the number of transactions that need to be further evaluated. If the screen is not met, this ASU requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and also remove the evaluation of whether a market participant could replace missing elements. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-01 did not have a material impact on the Company’s condensed consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”). This ASU eliminates Step 2 from the goodwill impairment test if the carrying amount exceeds the fair value of a reporting unit and also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. This update is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently assessing the impact the adoption of ASU 2017-04 will have on the Company’s condensed consolidated financial statements. In May 2017, the FASB issued ASU No. 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”), to clarify which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This ASU is effective for annual periods beginning after December 15, 2017. ASU 2017-09 will be applied prospectively when changes to the terms or conditions of a share-based payment award occur. The Company adopted ASU 2017-01 on January 1, 2018. The adoption of ASU 2017-09 did not have a material impact on the Company’s condensed consolidated financial statements. In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception” (“ASU 2017-11”). The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. The amendments in Part 1 of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in any interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The Company is currently assessing the impact the adoption of ASU 2017-11 will have on the Company’s condensed consolidated financial statements. With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company’s financial position, results of operations and cash flows.

Basis of Presentation and Sum24

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The Company had major payors that contributed the following percentage of net revenue: For The Three Months 2018 2017 Payor A * % 12.9 % Payor B 12.0 % 24.0 % Payor C * % 11.9 % Payor D 10.9 % 12.7 % * Less than 10% of total net revenues The Company had major payors that contributed to the following percentage of receivables before the allowance for doubtful accounts: As of March As of December Payor D 25.6 % 23.8 % Payor E 38.2 % 30.5 %
Fair Value Measurements, Recurring and Nonrecurring	The carrying amounts and fair values of the Company’s financial instruments as of March 31, 2018 are presented below: Fair Value Measurements Level 1 Level 2 Level 3 Total Assets Money market accounts* $ 42,300,818 $ - $ - $ 42,300,818 Marketable securities – certificates of deposit 1,061,022 - - 1,061,022 Marketable securities – equity securities 77,455 - - 77,455 Total $ 43,439,295 $ - $ - $ 43,439,295 The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2017 are presented below: Fair Value Measurements Level 1 Level 2 Level 3 Total Assets Money market accounts* $ 41,231,405 $ - $ - $ 41,231,405 Marketable securities – certificates of deposit 1,057,090 - - 1,057,090 Marketable securities – equity securities 86,005 - - 86,005 Total $ 42,374,500 $ - $ - $ 42,374,500
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation	The following summarizes activity of Level 3 inputs measured on a recurring basis for the three months ended March 31, 2017: Derivative Balance at January 1, 2017 $ 5,338,886 Change in fair value of warrant liabilities 1,522,222 Balance at March 31, 2017 $ 6,861,108

Mergers and Acquisitions (Table

Mergers and Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2018
Schedule of Business Acquisitions, by Acquisition	Total estimated purchase consideration consisted of the following: Equity consideration (1) $ 61,092,050 Estimated fair value of ApolloMed preferred stock held by NMM (2) 19,118,000 Estimated fair value of NMM’s noncontrolling interest in APAACO (3) 5,129,000 Estimated fair value of the outstanding ApolloMed stock options (4) 187,333 Total estimated purchase consideration $ 85,526,383 (1) Equity consideration Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 (2) Estimated fair value of ApolloMed’s preferred shares held by NMM NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger. As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed. The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A and Series B preferred stock were valued to be $ 19,118,000 2 37.9 1.8 12,745,000 6,373,000 (3) Estimated fair value of NMM’s 50% share of APA ACO Inc. Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM’s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM’s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger. (4) Estimated fair value of the ApolloMed outstanding stock options The estimated fair value of the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated with the awards. There is no future service requirement.
Business Combination, Equity consideration	Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders (1) 6,109,205 Multiplied by the price per share of ApolloMed’s common stock (2) $ 10.00 Equity consideration $ 61,092,050 (1) Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger. (2) Represents the closing price of ApolloMed’s common stock on December 8, 2017.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	Under the acquisition method of accounting, the identifiable assets acquired and liabilities assumed of ApolloMed, the accounting acquiree, are recorded at the Merger date fair values and added to those of NMM, the accounting acquirer. The following table sets forth the preliminary allocation of the purchase consideration to the identifiable tangible and intangible assets acquired and liabilities assumed of ApolloMed and MMG (see “MMG Transaction” below), with the excess recorded as goodwill: Assets acquired Cash and cash equivalents $ 36,367,555 Accounts receivable, net 7,261,588 Other receivables 3,211,028 Prepaid expenses 249,193 Property, plant and equipment, net 1,114,332 Restricted cash 745,220 Fair value of intangible assets acquired 14,984,000 Deferred tax assets 2,301,972 Other assets 217,241 Total assets acquired $ 66,452,129 Liabilities assumed Accounts payable and accrued liabilities $ 8,632,893 Medical liabilities 39,353,540 Line of credit 25,000 Convertible note payable, net 5,376,215 Convertible note payable - related party 9,921,938 Noncontrolling interest 3,142,000 Total liabilities assumed and noncontrolling interest $ 66,451,586 Net liabilities assumed $ (913,468) Goodwill $ 85,525,840
Business Acquisition, Pro Forma Information	The pro forma combined historical results, as if ApolloMed had been acquired as of January 1, 2017, are estimated as follows (unaudited): Three Months Net revenues $ 98,467,260 Net loss attributable to Apollo Medical Holdings, Inc. $ (351,982) Weighted average common shares outstanding: Basic 33,601,022 Earnings per share: basic $ (0.01) Weighted average common shares outstanding: diluted 33,601,022 Earnings per share: diluted $ (0.01)

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	At March 31, 2018, the Company’s intangible assets, net, consisted of the following: Useful Gross Net Life March 31, Accumulated March 31, (Years) 2018 Amortization 2018 Indefinite Lived Assets: Medicare license N/A $ 1,994,000 $ - $ 1,994,000 Amortized Intangible Assets: Network relationships 11-15 109,883,000 (39,179,025) 70,703,975 Management contracts 15 22,832,000 (5,646,843) 17,185,157 Member relationships 12 6,696,000 (357,292) 6,338,708 Patient management platform 5 2,060,000 (137,333) 1,922,667 Tradename/trademarks 20 1,011,000 (16,850) 994,150 $ 144,476,000 $ (45,337,343) $ 99,138,657 At December 31, 2017, the Company’s intangible assets, net, consisted of the following: Useful Gross Net Life December 31, Accumulated December 31, (Years) 2017 Amortization 2017 Indefinite Lived Assets: Medicare license N/A $ 1,994,000 $ - $ 1,994,000 Amortized Intangible Assets: Network relationships 11-15 109,883,000 (35,842,508) 74,040,492 Management contracts 15 22,832,000 (5,014,886) 17,817,114 Member relationships 12 6,696,000 (46,500) 6,649,500 Patient management platform 5 2,060,000 (34,336) 2,025,664 Tradename/trademarks 20 1,011,000 (4,212) 1,006,788 $ 144,476,000 $ (40,942,442) $ 103,533,558
Schedule of future amortization expense	Future amortization expense is estimated to be as follows for the years ending December 31: Amount 2018 (remaining nine months) $ 12,262,000 2019 14,480,000 2020 12,671,000 2021 10,961,000 2022 9,448,000 Thereafter 37,323,000 $ 97,145,000

Investments in Other Entities (

Investments in Other Entities (Tables)	3 Months Ended
	Mar. 31, 2018
Equity Method Investments	Investments in other entities – equity method consisted of the following: March 31, 2018 December 31, 2017 Universal Care, Inc. $ 8,589,253 $ 8,609,455 LaSalle Medical Associates – IPA Line of Business 9,099,975 9,452,767 Diagnostic Medical Group 2,176,453 1,847,411 Pacific Medical Imaging & Oncology Center, Inc. 1,374,668 1,400,693 Pacific Ambulatory Surgery Center, LLC 635,151 593,198 $ 21,875,500 $ 21,903,524
LaSalle Medical Associates IPA [Member]
Equity Method Investments	LMA’s IPA line of business summarized balance sheets at March 31, 2018 and December 31, 2017 and summarized statements of income for the three months ended March 31, 2018 and 2017 are as follows (unaudited): Balance Sheets March 31, 2018 December 31, 2017 Assets Cash and cash equivalents $ 22,064,701 $ 21,065,105 Receivables, net 3,005,144 2,433,116 Other current assets 2,173,110 1,565,606 Loan receivable 1,250,000 1,250,000 Restricted cash 664,612 662,109 Total assets $ 29,157,567 $ 26,975,936 Liabilities and Stockholders’ Equity March 31, 2018 December 31, 2017 Current liabilities $ 23,946,133 $ 20,353,337 Stockholders’ equity 5,211,434 6,622,599 Total liabilities and stockholders’ equity $ 29,157,567 $ 26,975,936 Statements of Income March 31, 2018 March 31, 2017 Revenues $ 52,983,791 $ 49,753,004 Expenses 54,002,458 44,506,050 Net (loss) income $ (1,018,667) $ 5,246,954
Universal Care Inc [Member]
Equity Method Investments	UCI’s balance sheets at March 31, 2018 and December 31, 2017 and statements of income for the three months ended March 31, 2018 and 2017 are as follows: Balance Sheets March 31, 2018 December 31, 2017 Assets Cash $ 22,595,206 $ 21,872,894 Receivables, net 23,862,184 18,618,760 Other current assets 18,870,831 13,021,520 Other assets 2,259,507 3,754,470 Property and equipment, net 1,770,157 1,576,621 Total assets $ 69,357,885 $ 58,844,265 Liabilities and Stockholders’ Deficit March 31, 2018 December 31, 2017 Current liabilities $ 64,984,078 $ 54,421,532 Other liabilities 10,044,340 10,051,952 Stockholders’ deficit (5,670,533) (5,629,219) Total liabilities and stockholders’ deficit $ 69,357,885 $ 58,844,265 Statements of Income Operations March 31, 2018 March 31, 2017 Revenues $ 72,665,437 $ 46,540,892 Expenses 72,154,950 44,757,246 Income before provision for income taxes 510,487 1,783,646 Provision for income taxes 551,800 713,500 Net (loss) income $ (41,313) $ 1,070,146

Accounts Payable and Accrued 28

Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Accounts payable and accrued liabilities	The Company’s accounts payable and accrued expenses consisted of the following: March 31, 2018 December 31, 2017 Accounts payable $ 3,356,677 $ 3,786,381 Specialty capitation payable 300,000 547,307 Subcontractor IPA risk pool payable 1,472,985 1,348,376 Professional fees 2,727,238 3,004,215 Deferred revenue 710,106 250,000 Accrued compensation 3,543,524 4,343,341 $ 12,110,530 $ 13,279,620

Medical Liabilities (Tables)

Medical Liabilities (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Medical Liabilities [Abstract]
Medical Liabilities	March 31, 2018 December 31, 2017 Balance, beginning of period $ 63,972,318 $ 18,957,465 Medical liabilities assumed from Merger - 39,353,540 Claims paid for previous period (28,633,287) (23,075,516) Incurred health care costs 44,634,257 121,846,375 Claims paid for current period (10,805,984) (92,476,160) Adjustments (56,478) (633,386) Balance, end of period $ 69,110,826 $ 63,972,318

Mezzanine and Stockholders_ E30

Mezzanine and Stockholders’ Equity (Tables)	3 Months Ended
	Mar. 31, 2018
Warrants Outstanding	The Company’s outstanding warrants consisted of the following: Shares Weighted Weighted Aggregate Warrants outstanding at January 1, 2017 3,648,541 $ 9.75 3.74 $ 14.25 Warrants granted - - - - Warrants exercised (191,625) 7.55 - 9.96 Warrants expired/forfeited (11,250) - - - Warrants outstanding at March 31, 2018 3,445,666 $ 9.88 3.69 $ 6.07 Weighted Weighted Average Average Exercise Price Exercise Price Per Warrants Remaining Warrants Per Share Outstanding Contractual Life Exercisable Share $ 4.50 24,000 0.60 24,000 $ 4.50 9.00 1,116,111 2.53 1,116,111 9.00 10.00 1,455,555 4.05 1,455,555 10.00 11.00 850,000 4.69 850,000 11.00 $ 4.50 –11.00 3,445,666 3.69 3,445,666 $ 9.88
Contracted physicians and other services [Member]
Stock Option Transactions Under Stock Option Plans	Share-based compensation expense related to option awards granted to primary care physicians to purchase shares of APC’s common stock, recognized over their respective vesting periods, consisted of the following: Three Months Ended March 31, 2018 2017 Contracted physicians and other services $ 202,382 $ 321,233
Exclusivity Amendment Agreement, APC [Member]
Stock Option Transactions Under Stock Option Plans	Outstanding stock options granted to primary care physicians to purchase shares of APC’s common stock consisted of the following: Shares Weighted Weighted Aggregate Options outstanding at January 1, 2018 853,800 $ 0.167 1.75 $ 508,864 Options granted - - - - Options exercised - - - - Options expired/forfeited - - - - Options outstanding at March 31, 2018 853,800 $ 0.167 1.50 $ 508,864 Options exercisable at March 31, 2018 853,800 $ 0.167 1.50 $ 508,864
Employee Stock Option [Member]
Stock Option Transactions Under Stock Option Plans	The Company’s outstanding stock options consisted of the following: Shares Weighted Weighted Aggregate Options outstanding at January 1, 2018 1,141,040 $ 3.95 5.79 $ 19.81 Options granted 30,000 9.25 - - Options exercised (129,536) 6.11 - 15.03 Options forfeited - - - - Options outstanding at March 31, 2018 1,041,504 $ 4.09 5.66 $ 11.86 Options exercisable at March 31, 2018 1,041,504 $ 4.09 5.66 $ 11.86

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2018
Revenue from Contract with Customer [Abstract]
Schedule of Prospective Adoption of New Accounting Pronouncements	The cumulative effect of changes made to the Company’s condensed consolidated balance sheet as of January 1, 2018 for the adoption of Topic 606 were as follows: Balance at Adjustments Balance at Current Assets Receivables $ 20,117,304 $ 11,600,000 $ 31,717,304 Liabilities, Mezzanine Equity and Stockholders’ Equity Noncurrent Liabilities Deferred tax liability $ 24,916,598 $ 3,246,098 $ 28,162,696 Mezzanine equity Noncontrolling interest in Allied Pacific of California IPA $ 172,129,744 $ 7,351,434 $ 179,481,178 Stockholders’ Equity Retained earnings $ 1,734,531 $ 1,002,468 $ 2,736,999
Disaggregation of Revenue	The following table presents disaggregated revenue generated by each payor type: March 31, 2018 March 31, 2017 Commercial $ 105,350,102 $ 83,848,918 Medicare 18,541,115 1,453,703 Medicaid 176,350 - Other third parties 99,160 33,441 Revenue $ 124,166,727 $ 85,336,062

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Below is a summary of the earnings per share computations: Three Months Ended March 31, 2018 2017 Earnings per share – basic $ 0.07 $ 0.17 Earnings per share – diluted $ 0.06 $ 0.15 Weighted average shares of common stock outstanding – basic 32,421,467 25,067,954 Weighted average shares of common stock outstanding – diluted 38,098,373 28,445,647
Schedule of Weighted Average Number of Shares	Below is a summary of the shares included in the diluted earnings per share computations: Three Months Ended March 31, 2018 2017 Weighted average shares of common stock outstanding – basic 32,421,467 25,067,954 10% shares held back pursuant to indemnification clause 3,039,749 2,785,328 Stock options 835,790 592,365 Warrants 1,801,367 - Weighted average shares of common stock outstanding – diluted 38,098,373 28,445,647

Variable Interest Entities (V33

Variable Interest Entities (VIEs) (Tables)	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Variable Interest Entities	The following table includes assets that can only be used to settle the liabilities of APC and the creditors of APC have no recourse to the Company. These assets and liabilities, with the exception of the investments in other entities – cost method and amounts due to affiliate, which are eliminated upon consolidation with the NMM, are included in the accompanying consolidated balance sheets. March 31, December 31, Assets Current assets Cash and cash equivalents $ 58,024,188 $ 54,686,370 Restricted cash – short-term 18,028,116 18,005,661 Fiduciary cash 1,386,474 2,017,437 Investment in marketable securities 1,061,022 1,057,090 Receivables, net 38,844,184 15,183,483 Prepaid expenses and other current assets 1,960,737 1,821,328 Total current assets 119,304,721 92,771,369 Noncurrent assets Land, property and equipment, net 10,201,045 10,167,689 Intangible assets, net 67,670,837 70,841,907 Goodwill 60,012,316 60,012,316 Loans receivable – related parties 5,000,000 5,000,000 Loan receivable 5,000,000 5,000,000 Investments in other entities – equity method 21,875,500 21,903,524 Investments in other entities – cost method 4,320,000 4,320,000 Restricted cash – long-term 745,293 745,235 Other assets 1,155,114 1,371,664 Total noncurrent assets 175,980,105 179,362,335 Total assets $ 295,284,826 $ 272,133,704 Current liabilities Accounts payable and accrued expenses $ 3,505,047 $ 3,625,610 Incentives payable 14,900,000 21,500,000 Fiduciary accounts payable 1,386,474 2,017,437 Medical liabilities 25,212,116 25,186,240 Income taxes payable 3,229,058 1,463,540 Amount due to affiliate 28,061,953 24,889,717 Bank loan, short-term 394,783 510,391 Capital lease obligations 99,480 98,738 Total current liabilities 76,788,911 79,291,673 Noncurrent liabilities Deferred tax liability 27,406,818 20,970,766 Liability for unissued equity shares 1,185,025 1,185,025 Capital lease obligations, net of current portion 593,852 619,001 Total noncurrent liabilities 29,185,695 22,774,792 Total liabilities $ 105,974,606 $ 102,066,465

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Nov. 15, 2016	Mar. 31, 2018	Dec. 31, 2011	Dec. 31, 2017	Jul. 31, 2016	May 31, 2016	Jun. 04, 2014
Description Of Business [Line Items]
Initial Fixed Term Of Amended and Restated Management and Administrative Services Agreement		30 years
ApolloMed [Member]
Description Of Business [Line Items]
Equity Method Investment, Ownership Percentage		4.90%		4.95%
Concourse Diagnostic Surgery Center, LLC [Member]
Description Of Business [Line Items]
Equity Method Investment, Ownership Percentage			41.59%		43.43%	43.80%
Payments to Acquire Equity Method Investments			$ 625,000
Universal Care Acquisition Partners, LLC [Member]
Description Of Business [Line Items]
Equity Method Investment, Ownership Percentage							100.00%
Pacific Ambulatory Surgery Center [Member]
Description Of Business [Line Items]
Equity Method Investment, Ownership Percentage		40.00%
International Cancer Center ICC” [Member]
Description Of Business [Line Items]
Proceeds from Issuance of Common Stock	$ 400,000
Equity Method Investment, Ownership Percentage	40.00%

Basis of Presentation and Sum35

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Summary Of Significant Accounting Policies [Line Items]
Cash, Uninsured Amount	$ 135,000,000
Restricted Cash	18,028,116		$ 18,005,661
Increase in Restricted Cash	18,000,000
Allowance for Doubtful Accounts Receivable, Current	$ 763,205		$ 407,953
Equity Method Investment, Significant Influence Description	Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investees board of directors, are considered in determining whether the equity method of accounting is appropriate.
Warrant Liability [Member]
Summary Of Significant Accounting Policies [Line Items]
Share Price		$ 9
Percentage For Down round financing		0.00%
Derivative Asset, Noncurrent		$ 6,900,000
Maximum
Summary Of Significant Accounting Policies [Line Items]
Restricted Cash Interest Rate	0.10%
Maximum | Warrant Liability [Member]
Summary Of Significant Accounting Policies [Line Items]
Expected term		4 years
Risk free interest rate		1.71%
Expected volatility rate		62.30%
Minimum
Summary Of Significant Accounting Policies [Line Items]
Restricted Cash Interest Rate	0.05%
Minimum | Warrant Liability [Member]
Summary Of Significant Accounting Policies [Line Items]
Expected term		3 years 6 months 14 days
Risk free interest rate		1.62%
Expected volatility rate		62.40%
APA ACO [Member]
Summary Of Significant Accounting Policies [Line Items]
Estimated Revenue Percentage	100.00%

Percentage of Net Revenue and T

Percentage of Net Revenue and Total Accounts Receivable (Detail)	1 Months Ended		3 Months Ended
	Mar. 23, 2018	[1]	Mar. 31, 2018	Mar. 31, 2017
Sales Revenue, Net | Payor A [Member]
Accounts Receivable And Net Revenue [Line Items]
Concentration Risk, Percentage				12.90%
Sales Revenue, Net | Payor B [Member]
Accounts Receivable And Net Revenue [Line Items]
Concentration Risk, Percentage			12.00%	24.00%
Sales Revenue, Net | Payor C [Member]
Accounts Receivable And Net Revenue [Line Items]
Concentration Risk, Percentage				11.90%
Sales Revenue, Net | Payor D [Member]
Accounts Receivable And Net Revenue [Line Items]
Concentration Risk, Percentage			10.90%	12.70%
Accounts Receivable | Payor D [Member]
Accounts Receivable And Net Revenue [Line Items]
Concentration Risk, Percentage			25.60%	23.80%
Accounts Receivable | Payor E [Member]
Accounts Receivable And Net Revenue [Line Items]
Concentration Risk, Percentage			38.20%	30.50%
[1]	Less than 10% of total net revenues

Carrying Amounts and Fair Value

Carrying Amounts and Fair Values of Company's Financial Instruments (Detail) - USD ($)		Mar. 31, 2018	Dec. 31, 2017
Assets
Assets, Fair Value Disclosure		$ 43,439,295	$ 42,374,500
Fair Value, Inputs, Level 1 [Member]
Assets
Assets, Fair Value Disclosure		43,439,295	42,374,500
Fair Value, Inputs, Level 2 [Member]
Assets
Assets, Fair Value Disclosure		0	0
Fair Value, Inputs, Level 3 [Member]
Assets
Assets, Fair Value Disclosure		0	0
Money Market Funds [Member]
Assets
Assets, Fair Value Disclosure	[1]	42,300,818	41,231,405
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Assets, Fair Value Disclosure	[1]	42,300,818	41,231,405
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets
Assets, Fair Value Disclosure	[1]	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets
Assets, Fair Value Disclosure	[1]	0	0
Certificates of Deposit [Member]
Assets
Assets, Fair Value Disclosure		1,061,022	1,057,090
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Assets, Fair Value Disclosure		1,061,022	1,057,090
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Assets
Assets, Fair Value Disclosure		0	0
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]
Assets
Assets, Fair Value Disclosure		0	0
Equity Securities [Member]
Assets
Assets, Fair Value Disclosure		77,455	86,005
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets
Assets, Fair Value Disclosure		77,455	86,005
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets
Assets, Fair Value Disclosure		0	0
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets
Assets, Fair Value Disclosure		$ 0	$ 0
[1]	Included in cash and cash equivalents

Summarizes activity of Level 3

Summarizes activity of Level 3 inputs measured on a recurring basis (Detail)	3 Months Ended
	Mar. 31, 2017USD ($)
Beginning Balance	$ 5,338,886
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Period Increase (Decrease)	1,522,222
Ending Balance	$ 6,861,108

Mergers and Acquisitions - Addi

Mergers and Acquisitions - Additional Information (Detail) - USD ($)		Dec. 08, 2017	Mar. 30, 2017	Mar. 31, 2018	Dec. 31, 2017
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 9.88	$ 9.75
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	[1]			6,109,205
Payments for Agreement Termination				$ 400,000
Increase Decrease Deferred Tax Asset				900,000
Preferred Stock [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	[2]			$ 19,118,000
APA ACO, Inc [Member]
Equity Method Investment, Ownership Percentage				50.00%
Network Medical Management, Inc. [Member]
Payments for Agreement Termination				$ 400,000
Network Medical Management, Inc. [Member] | Noncontrolling Interest [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	[3]			$ 5,129,000
Network Medical Management, Inc. [Member] | APA ACO, Inc [Member]
Equity Method Investment, Ownership Percentage				50.00%
Apollo Medical Holdings, Inc [Member]
Business Combination, Step Acquisition, Equity Interest in Acquire, Number of Share		2,566,666
Business Acquisition, Percentage of Voting Interests Acquired		82.00%
Business Combination, Consideration Description				The consideration for the transaction was 18% of the total issued and outstanding shares of ApolloMed common stock, or 6,109,205 (immediately following the Merger).
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		6,109,205
Fair Value Assumptions, Expected Term				2 years
Fair Value Assumptions, Expected Volatility Rate				37.90%
Fair Value Assumptions, Risk Free Interest Rate				1.80%
Preferred Stock, Liquidation Preference, Value				$ 12,745,000
Apollo Medical Holdings, Inc [Member] | Convertible Promissory Note [Member]
Debt Conversion, Converted Instrument, Shares Issued			520,081
Debt Conversion, Converted Instrument, Amount			$ 4,990,000
Apollo Medical Holdings, Inc [Member] | Warrant One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		850,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 11
Apollo Medical Holdings, Inc [Member] | Warrant Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		900,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 10
Maverick Medical Group, Inc [Member]
Business Combination, Contingent Consideration, Asset				100
Common Class B [Member] | Apollo Medical Holdings, Inc [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value				$ 6,373,000
[1]	Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.
[2]	Estimated fair value of ApolloMed’s preferred shares held by NMM NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger. As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed. The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A preferred stock and Series B preferred stock were valued to be $19,118,000. The valuation methodology was based on an Option Pricing Method (“OPM”) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company. OPM assumptions included an expected term of 2 years, volatility rate of 37.9%, and a risk-free rate of 1.8%. The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be $12,745,000 and the fair value of the conversion option was determined to be $6,373,000 or an aggregate total fair value of $19,118,000.
[3]	Estimated fair value of NMM’s 50% share of APA ACO Inc. Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM’s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM’s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger.

Total Estimated Purchase Consid

Total Estimated Purchase Consideration (Detail)	3 Months Ended
	Mar. 31, 2018USD ($)
Equity consideration	$ 61,092,050	[1]
Total estimated purchase consideration	85,526,383
Employee Stock Option [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	187,333	[2]
Preferred Stock [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	19,118,000	[3]
Network Medical Management, Inc. [Member] | Noncontrolling Interest [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	$ 5,129,000	[4]
[1]	Equity consideration Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 shares of ApolloMed common stock.
[2]	Estimated fair value of the ApolloMed outstanding stock options The estimated fair value of the outstanding ApolloMed stock options is included in consideration transferred in accordance with ASC 805. The outstanding ApolloMed stock options are expected to vest in conjunction with the Merger due to a pre-existing change-of-control provision associated with the awards. There is no future service requirement.
[3]	Estimated fair value of ApolloMed’s preferred shares held by NMM NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger. As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed. The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A preferred stock and Series B preferred stock were valued to be $19,118,000. The valuation methodology was based on an Option Pricing Method (“OPM”) which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company. OPM assumptions included an expected term of 2 years, volatility rate of 37.9%, and a risk-free rate of 1.8%. The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be $12,745,000 and the fair value of the conversion option was determined to be $6,373,000 or an aggregate total fair value of $19,118,000.
[4]	Estimated fair value of NMM’s 50% share of APA ACO Inc. Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM’s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM’s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger.

Calculated Based on Number of S

Calculated Based on Number of Shares of Combined Company Pre-Merger (Detail)	3 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Number of shares of the combined company that would be owned by pre-Merger ApolloMed stockholders | shares	6,109,205	[1]
Multiplied by the price per share of ApolloMed’s common stock | $ / shares	$ 10	[2]
Equity consideration | $	$ 61,092,050	[3]
[1]	Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.
[2]	Represents the closing price of ApolloMed’s common stock on December 8, 2017.
[3]	Equity consideration Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 shares of ApolloMed common stock.

Assumption of Identifiable Asse

Assumption of Identifiable Assets Acquired and Liabilities (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Assets acquired
Cash and cash equivalents	$ 36,367,555
Accounts receivable, net	7,261,588
Other receivables	3,211,028
Prepaid expenses	249,193
Property, plant and equipment, net	1,114,332
Restricted cash	745,220
Fair value of intangible assets acquired	14,984,000
Deferred tax assets	2,301,972
Other assets	217,241
Total assets acquired	66,452,129
Liabilities assumed
Accounts payable and accrued liabilities	8,632,893
Medical liabilities	39,353,540
Line of credit	25,000
Convertible note payable, net	5,376,215
Convertible note payable - related party	9,921,938
Noncontrolling interest	3,142,000
Total liabilities assumed and noncontrolling interest	66,451,586
Net liabilities assumed	(913,468)
Goodwill	$ 188,933,191	$ 189,847,202

Pro Forma Combined Historical R

Pro Forma Combined Historical Results (Detail)	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares
Net revenues | $	$ 98,467,260
Net loss attributable to Apollo Medical Holdings, Inc. | $	$ (351,982)
Weighted average common shares outstanding:
Basic | shares	33,601,022
Earnings per share:
basic | $ / shares	$ (0.01)
Weighted average common shares outstanding:
diluted | shares	33,601,022
Earnings per share:
diluted | $ / shares	$ (0.01)

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Finite Lived Intangible Assets Accumulated Amortization Addition	$ 4,394,901	$ 4,374,841
Exclusivity [Member]
Finite Lived Intangible Assets Accumulated Amortization Addition	$ 106,000

Schedule of intangible assets (

Schedule of intangible assets (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	$ (45,337,343)	$ (40,942,442)
Intangible Assets, Net	99,138,657	103,533,558
Intangible Assets, Gross, Total, Ending Balance	144,476,000
Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross, Total, Beginning Balance		144,476,000
Intangible Assets, Net		103,533,558
Intangible Assets, Gross, Total, Ending Balance			$ 144,476,000
Medicare License | Indefinite-lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated Amortization	0	0
Intangible Assets, Net	1,994,000	1,994,000
Indefinite Lived Assets, Gross, Beginning Balance		$ 1,994,000
Intangible Assets, Gross, Total, Ending Balance	$ 1,994,000
Network relationships | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Yrs)	15 years	15 years
Network relationships | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Yrs)	11 years	11 years
Network relationships | Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross, Total, Beginning Balance		$ 109,883,000
Accumulated Amortization	$ (39,179,025)			$ (35,842,508)
Intangible Assets, Net	70,703,975	$ 74,040,492
Intangible Assets, Gross, Total, Ending Balance	$ 109,883,000		109,883,000
Trade name
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Yrs)	20 years	20 years
Accumulated Amortization		$ (4,212)
Trade name | Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross, Total, Beginning Balance		1,011,000
Accumulated Amortization	$ (16,850)
Intangible Assets, Net	994,150	1,006,788
Intangible Assets, Gross, Total, Ending Balance	$ 1,011,000		$ 1,011,000
Management contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Yrs)	15 years		15 years
Management contracts [Member] | Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross, Total, Beginning Balance		22,832,000
Accumulated Amortization	$ (5,646,843)	(5,014,886)
Intangible Assets, Net	17,185,157	$ 17,817,114
Intangible Assets, Gross, Total, Ending Balance	$ 22,832,000		$ 22,832,000
Member relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Yrs)	12 years	12 years
Member relationships [Member] | Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross, Total, Beginning Balance		$ 6,696,000
Accumulated Amortization	$ (357,292)	(46,500)
Intangible Assets, Net	6,338,708	$ 6,649,500
Intangible Assets, Gross, Total, Ending Balance	$ 6,696,000		6,696,000
Patient management platform [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (Yrs)	5 years	5 years
Accumulated Amortization		$ (34,336)
Patient management platform [Member] | Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross, Total, Beginning Balance		2,060,000
Accumulated Amortization	$ (137,333)
Intangible Assets, Net	1,922,667	$ 2,025,664
Intangible Assets, Gross, Total, Ending Balance	$ 2,060,000		$ 2,060,000

Schedule of future amortization

Schedule of future amortization expense (Detail)	Mar. 31, 2018USD ($)
Finite-Lived Intangible Assets [Line Items]
2018 (remaining nine months)	$ 12,262,000
2,019	14,480,000
2,020	12,671,000
2,021	10,961,000
2,022	9,448,000
Thereafter	37,323,000
Total	$ 97,145,000

Investments in Other Entities -

Investments in Other Entities - Additional Information (Detail) - USD ($)	May 14, 2016	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2015	Dec. 31, 2017	Nov. 15, 2016	Aug. 10, 2015	Jul. 01, 2015	Dec. 31, 2012	Oct. 15, 2012
Income (Loss) from Equity Method Investments		$ (28,024)	$ 2,227,262
Equity Method Investments		21,875,500			$ 21,903,524
Due from Related Parties, Noncurrent		5,000,000			5,000,000
LaSalle Medical Associates IPA [Member]
Equity Method Investments		9,099,975			9,452,767
Pacific Medical Imaging and Oncology Center, Inc [Member]
Equity Method Investment, Ownership Percentage								40.00%
Equity Method Investment, Aggregate Cost								$ 1,200,000
Income (Loss) from Equity Method Investments		(26,025)	51,080
Equity Method Investments		1,374,668			1,400,693
Pacific Medical Imaging and Oncology Center, Inc [Member] | Ancillary Service Contract [Member]
Payments for Other Fees		400,000	500,000
Universal Care Inc [Member]
Equity Method Investments		$ 8,589,253			8,609,455
Payments for Advance to Affiliate				$ 5,000,000
Loans Receivable, Basis Spread on Variable Rate		1.00%
Due from Related Parties, Noncurrent		$ 5,000,000			$ 5,000,000
Loans Receivable, Interest Rate		5.75%			5.50%
Diagnostic Medical Group [Member]
Equity Method Investments		$ 2,176,453			$ 1,847,411
Payments to Acquire Equity Method Investments	$ 1,600,000
Pacific Ambulatory Surgery Center, LLC [Member]
Equity Method Investments		635,151			593,198
Allied Pacific of California [Member] | LaSalle Medical Associates IPA [Member]
Income (Loss) from Equity Method Investments		(352,792)	1,311,738
Equity Method Investments		9,099,975			9,452,767
Allied Pacific of California [Member] | Universal Care Inc [Member]
Income (Loss) from Equity Method Investments		(20,202)	523,301
Equity Method Investments		8,589,253			8,609,455
Allied Pacific of California [Member] | Diagnostic Medical Group [Member]
Income (Loss) from Equity Method Investments		329,042	361,644
Equity Method Investments		2,176,453			1,847,411
Allied Pacific of California [Member] | Pacific Ambulatory Surgery Center, LLC [Member]
Equity Method Investment, Ownership Percentage						40.00%
Equity Method Investment, Aggregate Cost						$ 800,000
Income (Loss) from Equity Method Investments		41,953	$ (20,501)
Equity Method Investments		$ 635,151			$ 593,198
APC LSMA [Member]
Equity Method Investment, Ownership Percentage	40.00%
APC LSMA [Member] | LaSalle Medical Associates IPA [Member]
Equity Method Investment, Ownership Percentage									25.00%
Equity Method Investment, Aggregate Cost									$ 5,000,000
APC LSMA [Member] | Allied Pacific of California [Member]
Equity Method Investment, Ownership Percentage										100.00%
Universal Care Acquisition Partners, LLC [Member] | Universal Care Inc [Member]
Equity Method Investment, Aggregate Cost							$ 10,000,000
Universal Care Acquisition Partners, LLC [Member] | Allied Pacific of California [Member]
Equity Method Investment, Ownership Percentage							100.00%
Voting Common Stock A Two [Member] | Universal Care Acquisition Partners, LLC [Member] | Universal Care Inc [Member]
Equity Method Investments, Purchase of Shares							100,000
Equity Method Investments, Proportion of Ownership Interest in Voting Common Stock							50.00%
Voting Common Stock A Two [Member] | Universal Care Acquisition Partners, LLC [Member] | Universal Care Inc [Member] | Ancillary Service Contract [Member]
Equity Method Investment, Ownership Percentage							48.90%

Investments in Other Entities48

Investments in Other Entities (Summarized Balance Sheets and Statements of Income) (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
LaSalle Medical Associates IPA [Member]
Equity Method Investment, Summarized Financial Information, Assets [Abstract]
Equity Method Investment, Summarized Financial Information, Cash and Cash Equivalents	$ 22,064,701		$ 21,065,105
Equity Method Investment, Summarized Financial Information, Receivables	3,005,144		2,433,116
Equity Method Investment, Summarized Financial Information, Other current assets	2,173,110		1,565,606
Equity Method Investment, Summarized Financial Information, Loan Receivables	1,250,000		1,250,000
Equity Method Investment, Summarized Financial Information, Restricted Cash	664,612		662,109
Equity Method Investment, Summarized Financial Information, Assets	29,157,567		26,975,936
Equity Method Investment, Summarized Financial Information, Liabilities and Equity [Abstract]
Equity Method Investment, Summarized Financial Information, Current Liabilities	23,946,133		20,353,337
Equity Method Investment Summarized Financial Information, Stockholders' deficit	5,211,434		6,622,599
Equity Method Investment, Summarized Financial Information, Total liabilities and stockholders' deficit	29,157,567		26,975,936
Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]
Equity Method Investment, Summarized Financial Information, Revenue	52,983,791	$ 49,753,004
Equity Method Investment, Summarized Financial Information, Expenses	54,002,458	44,506,050
Equity Method Investment, Summarized Financial Information, Net (loss) income	(1,018,667)	5,246,954
Universal Care Inc [Member]
Equity Method Investment, Summarized Financial Information, Assets [Abstract]
Equity Method Investment, Summarized Financial Information, Cash and Cash Equivalents	22,595,206		21,872,894
Equity Method Investment, Summarized Financial Information, Receivables	23,862,184		18,618,760
Equity Method Investment, Summarized Financial Information, Other current assets	18,870,831		13,021,520
Equity Method Investment, Summarized Financial Information, Other Assets	2,259,507		3,754,470
Equity Method Investment, Summarized Financial Information, Property And Equipment	1,770,157		1,576,621
Equity Method Investment, Summarized Financial Information, Assets	69,357,885		58,844,265
Equity Method Investment, Summarized Financial Information, Liabilities and Equity [Abstract]
Equity Method Investment, Summarized Financial Information, Current Liabilities	64,984,078		54,421,532
Equity Method Investment, Summarized Financial Information, Other Liabilities	10,044,340		10,051,952
Equity Method Investment Summarized Financial Information, Stockholders' deficit	(5,670,533)		(5,629,219)
Equity Method Investment, Summarized Financial Information, Total liabilities and stockholders' deficit	69,357,885		$ 58,844,265
Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]
Equity Method Investment, Summarized Financial Information, Revenue	72,665,437	46,540,892
Equity Method Investment, Summarized Financial Information, Expenses	72,154,950	44,757,246
Equity Method Investment, Summarized Financial Information, Income before provision for income taxes	510,487	1,783,646
Equity Method Investment, Summarized Financial Information, Provision for income taxes	551,800	713,500
Equity Method Investment, Summarized Financial Information, Net (loss) income	$ (41,313)	$ 1,070,146

Investments in Other Entities49

Investments in Other Entities (Equity Method) (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Equity Method Investments	$ 21,875,500	$ 21,903,524
Universal Care Inc [Member]
Equity Method Investments	8,589,253	8,609,455
LaSalle Medical Associates - IPA Line of Business [Member]
Equity Method Investments	9,099,975	9,452,767
Diagnostic Medical Group [Member]
Equity Method Investments	2,176,453	1,847,411
Pacific Medical Imaging and Oncology Center, Inc [Member]
Equity Method Investments	1,374,668	1,400,693
Pacific Ambulatory Surgery Center, LLC [Member]
Equity Method Investments	$ 635,151	$ 593,198

Loan Receivable - Additional In

Loan Receivable - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Loans Receivable, Net	$ 10,000,000	$ 10,000,000
Extendable Amount On Credit Facility	$ 8,000,000
Term Of Management Service Agreement	10 years
Percentage Of Managing Responsible Of Health Plan ship	100.00%
APC [Member]
Long-term Line of Credit	$ 5,000,000	5,000,000
NMM Business Loan Agreement [Member]
Long-term Line of Credit	$ 5,000,000	5,000,000
Dr. Jay Loan [Member]
Loans Receivable, Net		$ 10,000,000
Debt Instrument, Interest Rate, Basis for Effective Rate	prime rate plus 1%
Debt Instrument, Interest Rate, Stated Percentage	5.75%	5.50%
Debt Instrument, Payment Terms	Interest on the Dr. Jay Loan accrues at a rate that is equal to the prime rate plus 1% (5.75% and 5.50% as of March 31, 2018 and December 31, 2017, respectively) and payable in monthly installments of interest only on the first day of each month until the date that is 3 years following the initial date of funding, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full.
Debt Instrument, Convertible, Terms of Conversion Feature	At any time on or before the date that is one year following the initial funding date of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert up to $5,000,000 of the outstanding principal amount into shares of Accountables capital stock. At any time after the date that is one year following the funding date, the Dr. Jay Loan may be prepaid at any time. Within three years following the initial funding of the Dr. Jay Loan, APC-LSMA or its designee shall have the right, but not the obligation, to convert the then outstanding principal amount into Accountable shares based on Accountables then-current valuation.

Accounts payable and accrued 51

Accounts payable and accrued expenses (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Account Payable And Accrued Liabilities [Line Items]
Accounts payable	$ 3,356,677	$ 3,786,381
Specialty capitation payable	300,000	547,307
Subcontractor IPA risk pool payable	1,472,985	1,348,376
Professional fees	2,727,238	3,004,215
Deferred revenue	710,106	250,000
Accrued compensation	3,543,524	4,343,341
Accounts payable and accrued liabilities	$ 12,110,530	$ 13,279,620

Medical Liabilities (Detail)

Medical Liabilities (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Balance, beginning of period	$ 63,972,318	$ 18,957,465
Medical liabilities assumed from Merger	0	39,353,540
Claims paid for previous period	(28,633,287)	(23,075,516)
Incurred health care costs	44,634,257	121,846,375
Claims paid for current period	(10,805,984)	(92,476,160)
Adjustments	(56,478)	(633,386)
Balance, end of period	$ 69,110,826	$ 63,972,318

Bank Loan, Lines of Credit an53

Bank Loan, Lines of Credit and Loan Payable - Related Party - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Apr. 18, 2018	Mar. 31, 2018	Dec. 31, 2017	Apr. 07, 2017	Mar. 03, 2017	Apr. 22, 2016	Apr. 21, 2016	Apr. 30, 2012	Dec. 31, 2010
Short-term Bank Loans and Notes Payable		$ 394,783	$ 510,391
Subsequent Event [Member]
Debt Instrument, Maturity Date Range, Start	Apr. 22, 2018
Debt Instrument, Maturity Date Range, End	Jun. 22, 2018
ICC [Member]
Debt Instrument, Face Amount									$ 4,600,000
Debt Instrument, Interest Rate, Stated Percentage		4.75%	4.50%
Short-term Bank Loans and Notes Payable		$ 394,783	$ 510,391
Debt Instrument, Maturity Date		Dec. 31, 2018
APC [Member]
Line of Credit Facility, Expiration Date		Apr. 22, 2018
Long-term Line of Credit		$ 5,000,000	$ 5,000,000
Line of Credit Facility, Interest Rate Description		prime rate plus 0.125%
APC [Member] | Standby Letters of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 305,016
NMM Business Loan Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 20,000,000				$ 10,000,000
Line of Credit Facility, Interest Rate at Period End		4.875%	4.675%
Long-term Line of Credit		$ 5,000,000	$ 5,000,000
Line of Credit Facility, Remaining Borrowing Capacity		8,300,671
Line of Credit Facility, Guarantee Given by Related Parties		$ 1,000,000
APC Business Loan Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity						$ 10,000,000	$ 2,000,000
Line of Credit Facility, Interest Rate at Period End		4.875%	4.675%
Line of Credit Facility, Remaining Borrowing Capacity		$ 9,694,984	$ 9,694,984
Line of Credit Facility, Interest Rate Description		prime rate plus 0.125%
Line of Credit Facility, Guarantee Given by Related Parties		$ 1,000,000
APAACO [Member] | Standby Letters of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity					$ 6,699,329
Line of Credit Facility, Expiration Date		Apr. 22, 2018
Line of Credit Facility, Description		The letter of credit expires on December 31, 2018 and deemed automatically extended without amendment for additional one - year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date.

Mezzanine and Stockholders_ E54

Mezzanine and Stockholders’ Equity - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 21, 2018	Mar. 31, 2018	Dec. 31, 2017
Stock Issued During Period, Value, Stock Options Exercised		$ 479,000
Shares Issued, Price Per Share	$ 16.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		75,000
Treasury Stock, Common, Shares		1,682,110	1,682,110
Stock Issued During Period, Shares, Issued for Services	37,593
Stock Issued During Period, Value, Issued for Services	$ 631,562
Share-based Compensation Arrangement by Share-based Payment Award, Cashless Options, Exercises in Period		54,536
Share-based Compensation Arrangement by Share-based Payment Award, Cashless Options, Exercises in Period, Net		43,201
Share-based Compensation Arrangement by Share-based Payment Award, warrants, Exercises in Period		191,625
Warrant Issued During Period, Value, Stock Options Exercised		$ 1,400,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price		$ 2.10
Share-based Compensation Arrangement by Share-based Payment Award, Warrant, Exercisable, Weighted Average Exercise Price		4
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price		$ 10
Share-based Compensation Arrangement by Share-based Payment Award, Warrant, Exercisable, Weighted Average Exercise Price		10
Stock Compensation Plan [Member]
Share based Compensation Arrangement By Share based Payment Award Options Grant Weighted Average Remaining Contractual Term		1 year 6 months
Former Shareholders of NMM [Member]
Shares, Outstanding		1,000,970
Network Medical Management, Inc 'NMM' [Member] | Stock Compensation Plan [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		$ 1,214,292
AMEH [Member]
Stock Repurchased During Period, Shares		3,039,749
Allied Pacific of California [Member]
Treasury Stock, Common, Shares		1,682,110

Schedule of Stock Options Activ

Schedule of Stock Options Activity (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Shares
Options exercised	(75,000)
Employee Stock Option [Member]
Shares
Beginning balance	1,141,040
Options granted	30,000
Options exercised	(129,536)
Options forfeited	0
Ending balance	1,041,504	1,141,040
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	1,041,504
Weighted Average Exercise Price
Beginning balance	$ 3.95
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	9.25
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	6.11
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	0
Ending balance	4.09	$ 3.95
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 4.09
Weighted Average Remaining Contractual Term (Years)
Beginning Balance	5 years 7 months 28 days	5 years 9 months 14 days
Options exercisable	5 years 7 months 28 days
Aggregate Intrinsic Value
Beginning Balance	$ 19.81
Options exercised	15.03
Ending balance	11.86	$ 19.81
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 11.86
Allied Pacific of California [Member]
Shares
Beginning balance	853,800
Options granted	0
Options exercised	0
Options forfeited	0
Ending balance	853,800	853,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	853,800
Weighted Average Exercise Price
Beginning balance	$ 0.167
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	0
Ending balance	0.167	$ 0.167
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 0.167
Weighted Average Remaining Contractual Term (Years)
Beginning Balance	1 year 6 months	1 year 9 months
Options exercisable	1 year 6 months
Aggregate Intrinsic Value
Beginning Balance	$ 508,864
Ending balance	508,864	$ 508,864
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 508,864

Summary of Share-based Compensa

Summary of Share-based Compensation Expense Related to Common Stock Option Awards Granted (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Contracted physicians and other services [Member]
Share-based Compensation	$ 202,382	$ 321,233

Summary of Warrant (Detail)

Summary of Warrant (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Shares [Abstract]
Number of warrants, Outstanding	3,648,541
Number Of Warrants Granted	0
Number Of Warrants Exercised	(191,625)
Class Of Warrant Or Right Cancelled In Period	(11,250)
Number of warrants, Outstanding	3,445,666	3,648,541
Weighted Average Exercise Price [Abstract]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.75
Class Of Warrants Or Right, Exercise Price Of Warrants Grant In Period	0
Class Of Warrants Or Right, Exercise Price Of Warrants Exercised In Period	7.55
Class Of Warrants Or Right, Exercise Price Of Warrants Forfeited In Period	0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.88	$ 9.75
Weighted Average Remaining Contractual Term Years [Abstract]
Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term	0 years
Class Of Warrant Or Rights Exercised Weighted Average Remaining Contractual Term	0 years
Class Of Warrant Or Rights Forfeited Weighted Average Remaining Contractual Term	0 years
Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term	3 years 8 months 8 days	3 years 8 months 26 days
Aggregate Intrinsic Value [Abstract]
Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value	$ 14.25
Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value	0
Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value	9.96
Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value	0
Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value	$ 6.07	$ 14.25

Warrants (Detail)

Warrants (Detail)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Class of Warrant or Right [Line Items]
Weighted average remaining contractual life	0 years
Warrant Exercise Price Range One 4.50
Class of Warrant or Right [Line Items]
Warrants outstanding	24,000
Weighted average remaining contractual life	7 months 6 days
Warrants exercisable	24,000
Weighted average exercise price per share | $ / shares	$ 4.50
Warrant Exercise Price Range Two 9.00
Class of Warrant or Right [Line Items]
Warrants outstanding	1,116,111
Weighted average remaining contractual life	2 years 6 months 11 days
Warrants exercisable	1,116,111
Weighted average exercise price per share | $ / shares	$ 9
Warrant Exercise Price Range Three 10.00
Class of Warrant or Right [Line Items]
Warrants outstanding	1,455,555
Weighted average remaining contractual life	4 years 18 days
Warrants exercisable	1,455,555
Weighted average exercise price per share | $ / shares	$ 10
Warrant Exercise Price Range Four 11.00
Class of Warrant or Right [Line Items]
Warrants outstanding	850,000
Weighted average remaining contractual life	4 years 8 months 8 days
Warrants exercisable	850,000
Weighted average exercise price per share | $ / shares	$ 11
Warrant Exercise Price Range Five 4.50-11.00
Class of Warrant or Right [Line Items]
Warrants outstanding	3,445,666
Weighted average remaining contractual life	3 years 8 months 8 days
Warrants exercisable	3,445,666
Weighted average exercise price per share | $ / shares	$ 9.88

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	1 Months Ended
	Apr. 30, 2018USD ($)
Subsequent Event [Member]
Commitments And Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 5

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Nov. 16, 2015	Sep. 30, 2015
LMA [Member]
Equity Method Investment, Ownership Percentage	25.00%
Revenue from Related Parties	$ 4,600,000	$ 4,500,000
PMIOC [Member]
Equity Method Investment, Ownership Percentage	40.00%
DMG [Member]
Equity Method Investment, Ownership Percentage	40.00%
Payment Made To Related Party	$ 1,600,000	1,400,000
Service [Member] | PMIOC [Member]
Payment Made To Related Party	400,000	500,000
Service [Member] | AMG, Inc [Member]
Payment Made To Related Party	700,000	800,000
Rob Mikitarian [Member] | Notes Receivable [Member]
Debt Instrument, Face Amount					$ 150,000
Debt Instrument, Interest Rate, Effective Percentage					3.00%
Accounts and Other Receivables, Net, Current	150,000		$ 150,000
Universal Care Inc [Member]
Accounts and Other Receivables, Net, Current				$ 5,000,000
Equity Method Investment, Ownership Percentage				48.90%
Advance Diagnostic Surgery Center [Member] | Service [Member]
Payment Made To Related Party	22,000	34,000
Medical Property Partners [Member] | Service [Member]
Payment Made To Related Party	300,000	300,000
Medical Investment Group LLC [Member]
Payment Made To Related Party	90,000	90,000
APC Shareholders [Member]
Payment Made To Related Party	9,200,000	12,800,000
Shareholders And Officers [Member]
Payment Made To Related Party	$ 2,300,000	$ 5,400,000

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($)	Jan. 02, 2018	Mar. 31, 2018	Jan. 31, 2018	Dec. 31, 2017
Equity, Fair Value Adjustment		$ 10,208,000
Cumulative Effect on Retained Earnings, Net of Tax	$ 1,392,000	1,392,000
Fresh-Start Adjustment, Increase (Decrease), Deferred Income Tax Liabilities, Noncurrent		3,246,098
Contract with Customer, Liability		710,106		$ 250,000
All-Inclusive Population-Based Payments to be Received			$ 7,300,000
Accounts Receivable, Net, Current, Total		$ 52,805,123		20,117,304
Accounting Standards Update 2014-09 [Member]
Accounts Receivable, Net, Current, Total	$ 11,600,000			$ 11,600,000

Schedule of Prospective Adoptio

Schedule of Prospective Adoption of New Accounting Pronouncements (Detail) - USD ($)	Mar. 31, 2018	Jan. 02, 2018	Dec. 31, 2017
Current Assets
Receivables	$ 52,805,123		$ 20,117,304
Noncurrent Liabilities
Deferred tax liability	30,055,819		24,916,598
Mezzanine equity
Noncontrolling interest in Allied Pacific of California IPA	190,654,312		172,129,744
Stockholders’ Equity
Retained earnings	$ 4,897,454		1,734,531
Accounting Standards Update 2014-09 [Member]
Current Assets
Receivables		$ 11,600,000	11,600,000
Noncurrent Liabilities
Deferred tax liability			3,246,098
Mezzanine equity
Noncontrolling interest in Allied Pacific of California IPA			7,351,434
Stockholders’ Equity
Retained earnings			1,002,468
Adjustments for New Accounting Principle, Early Adoption [Member]
Current Assets
Receivables			31,717,304
Noncurrent Liabilities
Deferred tax liability			28,162,696
Mezzanine equity
Noncontrolling interest in Allied Pacific of California IPA			179,481,178
Stockholders’ Equity
Retained earnings			$ 2,736,999

Disaggregation of Revenue (Deta

Disaggregation of Revenue (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue	$ 124,166,727	$ 85,336,062
Commercial [Member]
Revenue	105,350,102	83,848,918
Medicare [Member]
Revenue	18,541,115	1,453,703
Medicaid [Member]
Revenue	176,350	0
Other third parties [Member]
Revenue	$ 99,160	$ 33,441

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%
Operating Loss Carryforwards, Limitation Rate on Taxable Income		80.00%
Increase Decrease in Deferred Tax Assets Due To Change in Enacted Tax Rate		$ 6.6
Increase Decrease in Deferred Tax Liabilities Due To Change in Enacted Tax Rate		16.3
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount		$ 9.7
Scenario, Plan [Member]
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Shares	1,682,110	1,682,110

Basic Net Income (loss) Per Sha

Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Earnings per share - basic	$ 0.07	$ 0.17
Earnings per share - diluted	$ 0.06	$ 0.15
Weighted average shares of common stock outstanding - basic	32,421,467	25,067,954
Weighted average shares of common stock outstanding - diluted	38,098,373	28,445,647

Summary of Shares Included in D

Summary of Shares Included in Diluted Earnings Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Weighted average shares of common stock outstanding - basic	32,421,467	25,067,954
Weighted average shares of common stock outstanding - diluted	38,098,373	28,445,647
Employee Stock Option [Member]
Weighted Average Number Diluted Shares Outstanding Adjustment	835,790	592,365
Common Stock [Member]
Weighted Average Number Diluted Shares Outstanding Adjustment	3,039,749	2,785,328
Warrant [Member]
Weighted Average Number Diluted Shares Outstanding Adjustment	1,801,367	0

VIE Assets - Additional Informa

VIE Assets - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2018USD ($)
Restricted Cash Acquired from Acquisition	$ 18,000,000

Eliminated Upon Consolidation I

Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 103,731,761	$ 99,749,199	$ 63,251,651
Restricted cash - short-term	18,028,116	18,005,661	0
Investment in marketable securities	1,138,477	1,143,095
Receivables, net	52,805,123	20,117,304
Prepaid expenses and other current assets	3,525,437	3,126,866
Total current assets	180,615,388	144,159,562
Noncurrent assets
Land, property and equipment, net	13,700,034	13,814,306
Intangible assets, net	99,138,657	103,533,558
Goodwill	188,933,191	189,847,202
Loans receivable - related parties	5,000,000	5,000,000
Loan receivable	10,000,000	10,000,000
Investments in other entities - equity method	21,875,500	21,903,524
Restricted cash - long-term	745,293	745,235	$ 101,132
Other assets	1,585,850	1,632,406
Total noncurrent assets	340,978,525	346,476,231
Total assets	521,593,913	490,635,793
Current liabilities
Accounts payable and accrued expenses	12,110,530	13,279,620
Fiduciary accounts payable	1,386,474	2,017,437
Medical liabilities	69,110,826	63,972,318		$ 18,957,465
Bank loan, short-term	394,783	510,391
Capital lease obligations	99,480	98,738
Total current liabilities	110,616,762	109,601,999
Noncurrent liabilities
Deferred tax liability	30,055,819	24,916,598
Liability for unissued equity shares	1,185,025	1,185,025
Capital lease obligations, net of current portion	593,852	619,001
Total noncurrent liabilities	49,834,696	44,720,624
Total liabilities	160,451,458	154,322,623
Variable Interest Entity, Primary Beneficiary [Member]
Current assets
Cash and cash equivalents	58,024,188	54,686,370
Restricted cash - short-term	18,028,116	18,005,661
Fiduciary cash	1,386,474	2,017,437
Investment in marketable securities	1,061,022	1,057,090
Receivables, net	38,844,184	15,183,483
Prepaid expenses and other current assets	1,960,737	1,821,328
Total current assets	119,304,721	92,771,369
Noncurrent assets
Land, property and equipment, net	10,201,045	10,167,689
Intangible assets, net	67,670,837	70,841,907
Goodwill	60,012,316	60,012,316
Loans receivable - related parties	5,000,000	5,000,000
Loan receivable	5,000,000	5,000,000
Investments in other entities - equity method	21,875,500	21,903,524
Investments in other entities - cost method	4,320,000	4,320,000
Restricted cash - long-term	745,293	745,235
Other assets	1,155,114	1,371,664
Total noncurrent assets	175,980,105	179,362,335
Total assets	295,284,826	272,133,704
Current liabilities
Accounts payable and accrued expenses	3,505,047	3,625,610
Incentives payable	14,900,000	21,500,000
Fiduciary accounts payable	1,386,474	2,017,437
Medical liabilities	25,212,116	25,186,240
Income taxes payable	3,229,058	1,463,540
Amount due to affiliate	28,061,953	24,889,717
Bank loan, short-term	394,783	510,391
Capital lease obligations	99,480	98,738
Total current liabilities	76,788,911	79,291,673
Noncurrent liabilities
Deferred tax liability	27,406,818	20,970,766
Liability for unissued equity shares	1,185,025	1,185,025
Capital lease obligations, net of current portion	593,852	619,001
Total noncurrent liabilities	29,185,695	22,774,792
Total liabilities	$ 105,974,606	$ 102,066,465

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	1 Months Ended
	Apr. 30, 2018USD ($)a	Mar. 31, 2018USD ($)
Subsequent Event [Line Items]
Dividends Payable | $		$ 8,000,000
Subsequent Event
Subsequent Event [Line Items]
Equity Method Investment, Ownership Percentage	50.00%
Dividends | $	$ 10,000,000
Subsequent Event | Building [Member]
Subsequent Event [Line Items]
Area of Land | a	89,000
Subsequent Event | Real Estate [Member]
Subsequent Event [Line Items]
Area of Land | a	109,000